

# CITATION REPORT

List of articles citing

## Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

DOI: 10.1038/nrneurol.2010.4

Nature Reviews Neurology, 2010, 6, 131-44.

**Source:** <https://exaly.com/paper-pdf/49573877/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1487	[11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. <i>Neurology</i> , <b>2003</b> , 61, 686-9	6.5	211
1486	Current Opinion in Neurology. Current world literature. <b>2010</b> , 23, 701-13		
1485	Acute effect on the A $\beta$ isoform pattern in CSF in response to $\beta$ -secretase modulator and inhibitor treatment in dogs. <b>2010</b> , 21, 1005-12		58
1484	Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. <b>2010</b> , 21, 1119-28		94
1483	Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. <b>2010</b> , 7, 919-29		20
1482	Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. <b>2010</b> , 119, 523-41		267
1481	Association of the RAGE G82S polymorphism with Alzheimer's disease. <b>2010</b> , 117, 861-7		36
1480	Proteomic studies on the development of the central nervous system and beyond. <b>2010</b> , 35, 1487-500		8
1479	Revising the definition of Alzheimer's disease: a new lexicon. <b>2010</b> , 9, 1118-27		1354
1478	Diagnosis and biomarkers of predementia in Alzheimer's disease. <b>2010</b> , 8, 89		76
1477	Current awareness in geriatric psychiatry. <b>2010</b> , 25, i-viii		
1476	Brain drain: A bottom-up approach to normal pressure hydrocephalus. <b>2010</b> , 68, 415-7		3
1475	Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. <b>2010</b> , 193, 296-9		5
1474	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <b>2010</b> , 16, 1223-6		63
1473	Biomarkers in Alzheimer's disease drug development. <b>2010</b> , 16, 1218-22		102
1472	CSF Biomarkers for Alzheimer's Disease Diagnosis. <b>2010</b> , 2010,		61
1471	Biological markers and Alzheimer disease: a canadian perspective. <b>2010</b> , 2010,		4

1470	Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid $\beta$ (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop. <b>2010</b> , 2010,	42
1469	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. <b>2010</b> , 2010,	14
1468	Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. <b>2010</b> , 2010,	132
1467	Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. <b>2010</b> , 2010,	20
1466	Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. <b>2010</b> , 10, 667-90	49
1465	Quantitative structural MRI for early detection of Alzheimer's disease. <b>2010</b> , 10, 1675-88	45
1464	From mild cognitive impairment to prodromal Alzheimer disease: A nosological evolution. <b>2010</b> , 1, 146-154	4
1463	Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. <b>2010</b> , 68, 913-21	37
1462	Regenerable and simultaneous surface plasmon resonance detection of $\alpha$ (1-40) and $\alpha$ (1-42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody. <b>2010</b> , 82, 10151-7	96
1461	Quantification of $\beta$ synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. <b>2010</b> , 4, 683-99	101
1460	BACE: Therapeutic target and potential biomarker for Alzheimer's disease. <b>2010</b> , 42, 1923-6	45
1459	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. <b>2010</b> , 6, 230-8	209
1458	Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. <b>2010</b> , 6, 367-77	36
1457	Cognitive intervention in Alzheimer disease. <i>Nature Reviews Neurology</i> , <b>2010</b> , 6, 508-17	15 117
1456	Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?. <b>2010</b> , 2, 8	16
1455	Bapineuzumab. <b>2010</b> , 10, 1121-30	70
1454	Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. <b>2010</b> , 2, 32	12
1453	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. <b>2011</b> , 3, 1	307

1452	Gene expression biomarkers in the brain of a mouse model for Alzheimer's disease: mining of microarray data by logic classification and feature selection. <b>2011</b> , 24, 721-38	86
1451	Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as $\beta$ -Amyloid PET Ligands and Identification of MK-3328. <b>2011</b> , 2, 498-502	16
1450	Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro. <b>2011</b> , 2, 500-5	89
1449	[Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice]. <b>2011</b> , 167, 474-84	10
1448	Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. <b>2011</b> , 70, 145-51	18
1447	Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future. <b>2011</b> , 8, 413-20	35
1446	Prevention in psychiatry: effects of healthy lifestyle on cognition. <b>2011</b> , 34, 249-61	18
1445	Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. <b>2011</b> , 15, 83-102	24
1444	CSF biomarkers in neurodegenerative diseases. <b>2011</b> , 49, 345-52	42
1443	Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis. <b>2011</b> , 17, 1301-12	41
1442	Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. <b>2011</b> , 26, 779-86	36
1441	Analytical aspects of proteomics: 2009-2010. <b>2011</b> , 83, 4407-26	26
1440	Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. <b>2011</b> , 144, 132-42	162
1439	Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. <b>2011</b> , 1814, 1785-95	49
1438	Systems biology of Alzheimer's disease: how diverse molecular changes result in memory impairment in AD. <b>2011</b> , 58, 739-50	22
1437	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. <b>2011</b> , 34, 430-42	235
1436	Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. <b>2011</b> , 17, 714-5	25
1435	Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library. <b>2011</b> , 32, 1232-43	24

1434	Presenilin mouse and zebrafish models for dementia: focus on neurogenesis. <b>2011</b> , 93, 149-64	30
1433	Biomarkers for Alzheimer's disease therapeutic trials. <b>2011</b> , 95, 579-93	100
1432	Biomarker-based dissection of neurodegenerative diseases. <b>2011</b> , 95, 520-34	66
1431	Discovery and development of integrative biological markers for schizophrenia. <b>2011</b> , 95, 686-702	25
1430	Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. <b>2011</b> , 95, 557-69	45
1429	Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. <b>2011</b> , 95, 491-5	34
1428	Perspectives of worldwide translational biomarker research in neurodegenerative diseases. <b>2011</b> , 95, 496-7	4
1427	Biomarkers for major depression and its delineation from neurodegenerative disorders. <b>2011</b> , 95, 703-17	30
1426	Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. <b>2011</b> , 95, 498-500	27
1425	The future of Alzheimer's disease: the next 10 years. <b>2011</b> , 95, 718-28	156
1424	Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. <b>2011</b> , 22, 482-7	140
1423	Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients. <b>2011</b> , 15, R297	114
1422	Revision of the criteria for Alzheimer's disease: A symposium. <b>2011</b> , 7, e1-12	27
1421	Global issues in drug development for Alzheimer's disease. <b>2011</b> , 7, 197-207	12
1420	How golden is the gold standard of neuropathology in dementia?. <b>2011</b> , 7, 486-9	48
1419	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <b>2011</b> , 7, 386-395.e6	291
1418	When will Alzheimer's disease be cured? A pharmaceutical perspective. <b>2011</b> , 24 Suppl 2, 43-52	14
1417	Focal Cortical Presentations Genetically Proven Alzheimer Disease. <b>2011</b> ,	

1416	Biomarkers for microglial activation in Alzheimer's disease. <b>2011</b> , 2011, 939426		18
1415	Cerebrospinal Fluid Levels of sAPP $\beta$ and sAPP $\tau$ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <b>2011</b> , 2011, 495025		16
1414	Detection of Soluble Amyloid- $\beta$ Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease. <b>2011</b> , 2011, 151645		14
1413	Proteomic Characterization of Cerebrospinal Fluid from Ataxia-Telangiectasia (A-T) Patients Using a LC/MS-Based Label-Free Protein Quantification Technology. <b>2011</b> , 2011, 578903		9
1412	Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid- $\beta$ is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. <b>2011</b> , 24, 25-34		53
1411	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , <b>2011</b> , 3, 1	5-3	53
1410	Biomarkers in Alzheimer's disease. <i>Frontiers in Neurology</i> , <b>2011</b> , 2, 46	4-1	14
1409	Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels. <b>2011</b> , 6, e29480		20
1408	Novel $\alpha$ -isoforms in Alzheimer's disease - their role in diagnosis and treatment. <b>2011</b> , 17, 2594-602		60
1407	BACE1 as a potential biomarker for Alzheimer's disease. <b>2011</b> , 24 Suppl 2, 53-9		41
1406	Amyloid- $\beta$ s associated with cognitive impairment in healthy elderly and subjective cognitive impairment. <b>2011</b> , 26, 135-42		67
1405	Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. <b>2011</b> , 18, 865-71		36
1404	Identifying and validating biomarkers for Alzheimer's disease. <b>2011</b> , 29, 26-32		321
1403	$\beta$ Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. <b>2011</b> , 10, 230-40		459
1402	Biochemical diagnosis of neurodegenerative diseases gets closer. <b>2011</b> , 10, 203-5		2
1401	Utility of imaging for nutritional intervention studies in Alzheimer's disease. <b>2011</b> , 668 Suppl 1, S59-69		12
1400	Plasma $\beta$ -amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. <b>2011</b> , 46, 590-6		37
1399	Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. <b>2011</b> , 81, 1422-34		38

1398	Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. <b>2011</b> , 68, 1145-51	36
1397	Identification of novel $\beta$ -synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. <b>2011</b> , 36, 2029-42	74
1396	Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain. <b>2011</b> , 118, 433-44	13
1395	No association of LOXL1 gene polymorphisms with Alzheimer's disease. <b>2011</b> , 13, 160-6	10
1394	Qualitative metabolome analysis of human cerebrospinal fluid by $^{13}\text{C}/^{12}\text{C}$ -isotope dansylation labeling combined with liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry. <b>2011</b> , 22, 339-47	43
1393	Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. <b>2011</b> , 11, 51	50
1392	Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. <b>2011</b> , 6, 69	59
1391	Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease. <b>2011</b> , 32, 2757-64	51
1390	Oxysterols as biomarkers in neurodegenerative diseases. <b>2011</b> , 164, 515-24	149
1389	A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. <b>2011</b> , 195, 143-50	44
1388	Predicting MCI outcome with clinically available MRI and CSF biomarkers. <i>Neurology</i> , <b>2011</b> , 77, 1619-28	6.5 160
1387	New diagnostic criteria for Alzheimer's disease. <b>2011</b> , 5, 407-9	4
1386	Using biomarkers to improve detection of Alzheimer's disease. <b>2011</b> , 1, 127-139	22
1385	Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment?. <b>2011</b> , 8, 164-74	77
1384	Progress in mining the human proteome for disease applications. <b>2011</b> , 15, 133-9	9
1383	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. <b>2011</b> , 108, 11848-53	165
1382	Diversity and disparity in dementia: the impact of ethnorracial differences in Alzheimer disease. <b>2011</b> , 25, 187-95	203
1381	Relationship between cholesterol metabolism, ApoE and brain volumes in Alzheimer's disease. <b>2011</b> , 6, 613-626	1

1380	Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid. <b>2011</b> , 31, 139-45		14
1379	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. <b>2011</b> , 49, 353-66		108
1378	Amyloid $\beta$ (A $\beta$ ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. <b>2011</b> , 49, 367-74		51
1377	Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis. <b>2011</b> , 5, 16-21		20
1376	Glaucoma and Alzheimer's disease in the elderly. <b>2011</b> , 7, 719-733		10
1375	Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. <b>2011</b> , 24, 529-34		32
1374	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. <b>2011</b> , 134, 301-17		109
1373	A window into the heterogeneity of human cerebrospinal fluid A $\beta$ peptides. <b>2011</b> , 2011, 697036		12
1372	Genome-wide association study of CSF biomarkers A $\beta$ 1-42, t-tau, and p-tau181p in the ADNI cohort. <i>Neurology</i> , <b>2011</b> , 76, 69-79	6.5	150
1371	Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. <b>2012</b> , 2012, 735206		97
1370	Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia. <b>2012</b> , 9, 257-66		15
1369	Alzheimer disease: can the exam predict the pathology?. <i>Neurology</i> , <b>2012</b> , 78, 374-5	6.5	7
1368	Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. <b>2012</b> , 69, 96-104		92
1367	Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. <b>2012</b> , 6, 455-76		83
1366	Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. <b>2012</b> , 33, 416-22		46
1365	Molecular Basis of Prion Diseases. <b>2012</b> , 872-885		1
1364	Rapidly progressive Alzheimer's disease: a multicenter update. <b>2012</b> , 30, 751-6		42
1363	Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. <i>Neurology</i> , <b>2012</b> , 78, 379-86	6.5	117



1362	Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. <b>2012</b> , 53, 592-600	73
1361	Cerebrospinal fluid levels of $\beta$ -amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. <b>2012</b> , 69, 98-106	459
1360	The role of tau in neurodegenerative diseases and its potential as a therapeutic target. <b>2012</b> , 2012, 796024	44
1359	Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. <b>2012</b> , 69, 1002-10	190
1358	Evaluation of the performance of novel A $\beta$ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient. <b>2012</b> , 10, 138-40	18
1357	Maternal family history is associated with Alzheimer's disease biomarkers. <b>2012</b> , 31, 659-68	45
1356	Diagnostic Tools: Fluid Biomarkers for Alzheimer's Disease. <b>2012</b> , 71-79	
1355	Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. <b>2012</b> , 30, 767-78	62
1354	Models for disease progression: new approaches and uses. <b>2012</b> , 92, 125-31	39
1353	Alzheimer's disease and the quest for its biological measures. <b>2013</b> , 33 Suppl 1, S237-41	5
1352	Translational research in neurology: dementia. <b>2012</b> , 69, 969-77	10
1351	The amyloid- $\beta$ isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. <b>2012</b> , 5, 1111-5	14
1350	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer's disease patients. <b>2012</b> , 7, 395-401	1
1349	Enriching amnesic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. <b>2012</b> , 32, 373-85	25
1348	Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. <i>Nature Reviews Neurology</i> , <b>2012</b> , 8, 598-600	15 33
1347	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , <b>2012</b> , 78, 468-76	6.5 133
1346	Evaluation of plasma A $\beta$ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. <b>2012</b> , 28, 231-8	37
1345	Role of proteomics in biomarker discovery and psychiatric disorders: current status, potentials, limitations and future challenges. <b>2012</b> , 9, 249-65	10

1344	Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. <b>2012</b> , 123, 396-405	48
1343	Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. <b>2012</b> , 53, 567-576	116
1342	Alzheimer's disease. <b>2012</b> , 65, 329-52	176
1341	Use of proteomic methods in the analysis of human body fluids in Alzheimer research. <b>2012</b> , 33, 3617-30	30
1340	Amyloid- $\beta$ metabolism in Niemann-Pick C disease models and patients. <b>2012</b> , 27, 573-85	35
1339	Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. <b>2012</b> , 53, 1868-76	53
1338	Mild cognitive impairment: disparity of incidence and prevalence estimates. <b>2012</b> , 8, 14-21	319
1337	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <b>2012</b> , 8, 65-73	210
1336	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. <b>2012</b> , 8, 312-36	92
1335	Multiplexing and multivariate analysis in neurodegeneration. <b>2012</b> , 56, 464-70	8
1334	A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid. <b>2012</b> , 56, 500-7	36
1333	Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. <b>2012</b> , 56, 494-9	8
1332	Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. <b>2012</b> , 56, 484-93	64
1331	Proteômica: metodologias e aplicações no estudo de doenças humanas. <b>2012</b> , 58, 366-375	4
1330	[Markers of prodromal Alzheimer's disease]. <b>2012</b> , 168, 815-24	
1329	[Multicenter study on lumbar puncture indication, clinical practice and feasibility]. <b>2012</b> , 168, 28-32	9
1328	Fluid biomarkers in Alzheimer disease. <b>2012</b> , 2, a006221	120
1327	Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. <b>2012</b> , 33, 831.e1-9	27

1326	Can Parkinson's disease pathology be propagated from one neuron to another?. <b>2012</b> , 97, 205-19	83
1325	Surfaces resistant to fouling from biological fluids: towards bioactive surfaces for real applications. <b>2012</b> , 12, 1413-22	73
1324	Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease. <b>2012</b> , 516, 302-5	67
1323	Complement activation as a biomarker for Alzheimer's disease. <b>2012</b> , 217, 204-15	48
1322	Preferential interactions between ApoE-containing lipoproteins and A $\beta$ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift. <b>2012</b> , 1821, 295-302	27
1321	DNA methylation of the 5'-untranslated region at +298 and +351 represses BACE1 expression in mouse BV-2 microglial cells. <b>2012</b> , 417, 387-92	18
1320	Characterization of plasma $\beta$ -secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. <b>2012</b> , 90, 2247-58	44
1319	New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. <b>2012</b> , 13, 84	4
1318	Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. <b>2012</b> , 10, 217	19
1317	Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. <b>2012</b> , 24, 244102	46
1316	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <b>2012</b> , 6, 419-30	230
1315	Plasma biomarkers for Alzheimer's disease: much needed but tough to find. <b>2012</b> , 6, 441-54	37
1314	Fluid biomarkers for Alzheimer's disease: standardization and recent developments. <b>2012</b> , 6, 363-4	1
1313	Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. <b>2012</b> , 69, 1445-52	327
1312	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid $\beta$ 42. <b>2012</b> , 6, 409-17	66
1311	Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. <b>2012</b> , 6, 401-7	20
1310	Diagnosis of Alzheimer's disease. <b>2012</b> , 12-46	
1309	Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease. <b>2012</b> , 71, 829-35	45

1308	Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. <b>2012</b> , 322, 192-6	22
1307	The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. <b>2012</b> , 322, 197-9	7
1306	Protease-activated drug development. <b>2012</b> , 2, 156-78	187
1305	Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. <b>2012</b> , 69, 836-41	241
1304	Biomarkers for Huntington's disease: an update. <b>2012</b> , 6, 371-5	9
1303	Clinical and research diagnostic criteria for Alzheimer's disease. <b>2012</b> , 22, 23-32,viii	39
1302	Alzheimer's disease: mimics and chameleons. <b>2012</b> , 12, 358-66	16
1301	Proteomics: methodologies and applications to the study of human diseases. <b>2012</b> , 58, 366-375	2
1300	Development of Antibody-Based Therapeutics. <b>2012</b> ,	5
1299	The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. <b>2012</b> , 16, 135-41	20
1298	Metals, membranes, and amyloid- $\beta$ oligomers: key pieces in the Alzheimer's disease puzzle?. <b>2013</b> , 33 Suppl 1, S283-93	18
1297	Amyloid- $\beta$ oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. <b>2012</b> , 29, 171-6	78
1296	Altered CSF orexin and $\beta$ synuclein levels in dementia patients. <b>2012</b> , 29, 125-32	79
1295	Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. <b>2012</b> , 7, e38639	56
1294	Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. <b>2012</b> , 7, e29868	79
1293	Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. <b>2012</b> , 7, e34341	58
1292	Peptidome analysis of cerebrospinal fluid by LC-MALDI MS. <b>2012</b> , 7, e42555	48
1291	CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. <b>2012</b> , 7, e33606	183

1290	Will posttranslational modifications of brain proteins provide novel serological markers for dementias?. <b>2012</b> , 2012, 209409	10
1289	Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. <b>2013</b> , 33 Suppl 1, S329-47	16
1288	Potential utility of soluble p3-alcadein plasma levels as a biomarker for sporadic Alzheimer's disease. <b>2012</b> , 31, 421-8	9
1287	Clinical, methodological and theoretical issues in the assessment of cognition after anaesthesia and surgery: a review. <b>2012</b> , 29, 409-22	28
1286	Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. <b>2012</b> , 30, 323-36	26
1285	[Early evaluation of Alzheimer's disease: biomarkers and neuropsychological tests]. <b>2012</b> , 140, 1191-200	2
1284	Reliable Measurements of the $\beta$ -Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. <b>2012</b> , 2012, 604141	38
1283	Linking atherosclerosis to Alzheimer's disease focus on biomarkers. <b>2012</b> , E4, 700-710	7
1282	Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer's disease. <b>2012</b> , 2012, 712048	8
1281	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. <i>Neurology</i> , <b>2012</b> , 78, 1568-75	6.5 172
1280	Investigation. <b>2012</b> , 107-137	
1279	The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. <b>2012</b> , 112, 5147-92	636
1278	Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. <b>2012</b> , 33, 2586-602	73
1277	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. <b>2012</b> , 124, 23-35	138
1276	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimer's disease and related conditions. <b>2012</b> , 2, 117-123	
1275	The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia. <b>2012</b> , 2, 211-219	1
1274	The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration. <b>2012</b> , 1, 94-103	
1273	[Advances in the diagnostics of Alzheimer's disease]. <b>2012</b> , 83, 661-73	6

1272	Cerebrospinal fluid profiles of amyloid $\beta$ -related biomarkers in Alzheimer's disease. <b>2012</b> , 14, 65-73	61
1271	Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. <b>2012</b> , 16, 339-45	31
1270	Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. <b>2012</b> , 119, 789-97	47
1269	Measurement of A $\beta$ 1-42 in cerebrospinal fluid is influenced by matrix effects. <b>2012</b> , 120, 325-33	29
1268	Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants. <b>2012</b> , 47, 347-52	21
1267	Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. <b>2012</b> , 235, 491-6	213
1266	Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. <b>2012</b> , 1253, 159-69	30
1265	Fluid biomarkers in Alzheimer's disease - current concepts. <b>2013</b> , 8, 20	147
1264	Plasma tau levels in Alzheimer's disease. <b>2013</b> , 5, 9	262
1263	Exploiting thermodynamic data to optimize the enantioseparation of underivatized amino acids in ligand exchange capillary electrophoresis. <b>2013</b> , 405, 951-9	12
1262	Diagnosis and management of the patient with suspected dementia in primary care. <b>2013</b> , 30, 667-76	10
1261	Is AD a homogeneous nosologic entity? Yes. <b>2013</b> , 120, 1467-73	
1260	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. <b>2013</b> , 101-102, 1-17	88
1259	Cognitive decline and cerebrospinal fluid biomarkers: a close relationship. <b>2013</b> , 8, 403-406	1
1258	Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. <b>2013</b> , 7, 641-62	16
1257	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. <b>2013</b> , 17, 54-63	24
1256	Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjögren's syndrome. <b>2013</b> , 42, 394-9	2
1255	Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. <b>2013</b> , 263, 553-60	38

1254	Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. <b>2013</b> , 263, 345-52	79
1253	Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. <b>2013</b> , 1, 217	154
1252	Identification of BACE1 inhibitors from Panax ginseng saponins-An Insilco approach. <b>2013</b> , 43, 1037-44	41
1251	Identification of $\beta$ -amyloid species in canine cerebrospinal fluid by mass spectrometry. <b>2013</b> , 34, 2125-32	9
1250	Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid. <b>2013</b> , 86, 26-36	30
1249	Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. <b>2013</b> , 38, 664-72	55
1248	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. <b>2013</b> , 54, 486-91	13
1247	Subpicogram per milliliter detection of interleukins using silicon photonic microring resonators and an enzymatic signal enhancement strategy. <b>2013</b> , 85, 10653-7	44
1246	Heart fatty acid binding protein and $\text{A}\beta$ -associated Alzheimer's neurodegeneration. <b>2013</b> , 8, 39	41
1245	Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. <b>2013</b> , 8, 1147-58	35
1244	Alzheimer disease: from biomarkers to diagnosis. <b>2013</b> , 169, 744-51	15
1243	A rapid and sensitive detection of ferritin at a nanomolar level and disruption of amyloid $\beta$ fibrils using fluorescent conjugated polymer. <b>2013</b> , 4, 5096	26
1242	Clinical indications for analysis of Alzheimer's disease CSF biomarkers. <b>2013</b> , 169, 709-14	16
1241	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. <b>2013</b> , 5, S8	14
1240	Changes in amyloid- $\beta$ and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. <b>2013</b> , 5, 194re2	125
1239	$\text{A}\beta$ 1-15/16 as a potential diagnostic marker in neurodegenerative diseases. <b>2013</b> , 15, 169-79	10
1238	Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid $\beta$ . <b>2013</b> , 57, 82-8	32
1237	Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. <i>Nature Reviews Neurology</i> , <b>2013</b> , 9, 201-10	15 390

1236	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. <b>2013</b> , 38, 1729-37	51
1235	Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease. <b>2013</b> , 9, 459-62	8
1234	The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. <b>2013</b> , 33, 923-8	9
1233	Translational proteomics in Alzheimer's disease and related disorders. <b>2013</b> , 46, 480-6	17
1232	Cerebrospinal fluid biomarkers in neurological diseases in children. <b>2013</b> , 17, 7-13	15
1231	Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease. <b>2013</b> , 544, 115-8	8
1230	Research and standardization in Alzheimer's trials: reaching international consensus. <b>2013</b> , 9, 160-8	16
1229	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. <b>2013</b> , 9, 406-13	51
1228	The missing link in the amyloid cascade of Alzheimer's disease - metal ions. <b>2013</b> , 62, 367-78	60
1227	24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases. <b>2013</b> , 95, 595-612	75
1226	Peripheral inflammation in neurodegeneration. <b>2013</b> , 91, 673-81	24
1225	Correlations between serum levels of beta amyloid, cerebrospinal levels of tau and phospho tau, and delayed response tasks in young and aged cynomolgus monkeys ( <i>Macaca fascicularis</i> ). <b>2013</b> , 42, 137-46	13
1224	miRNAs and long noncoding RNAs as biomarkers in human diseases. <b>2013</b> , 13, 183-204	111
1223	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- $\beta$ changes occur before increases of tau in cerebrospinal fluid. <b>2013</b> , 126, 631-41	103
1222	Development of a high-sensitivity immunoassay for amyloid-beta 1-42 using a silicon microarray platform. <b>2013</b> , 47, 490-5	56
1221	The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. <b>2013</b> , 97, 369-76	47
1220	Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. <b>2013</b> , 260, 620-6	67
1219	Peptides for immunological purposes: design, strategies and applications. <b>2013</b> , 45, 257-68	41



1218	Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. <i>Neurology</i> , <b>2013</b> , 81, 2103-6	6.5	110
1217	A selected reaction monitoring (SRM)-based method for absolute quantification of A $\beta$ 8, A $\beta$ 40, and A $\beta$ 42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. <b>2013</b> , 33, 1021-32		86
1216	Amyloid Chemical Probes and Theranostics: Steps Toward Personalized Medicine in Neurodegenerative Diseases. <b>2013</b> , 211-226		3
1215	Cerebrospinal fluid biomarkers of $\beta$ -amyloid metabolism in multiple sclerosis. <b>2013</b> , 19, 543-52		37
1214	Neurodegeneration, $\beta$ -amyloid and mood disorders: state of the art and future perspectives. <b>2013</b> , 28, 661-71		10
1213	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. <b>2013</b> , 28, 738-44		19
1212	Cerebrospinal fluid A $\beta$ 42, phosphorylated Tau181, and resting-state functional connectivity. <b>2013</b> , 70, 1242-8		68
1211	Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. <b>2013</b> , 27, 203-10		19
1210	Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease. <b>2013</b> , 3, 113-22		18
1209	CSF p-Tau levels in the prediction of Alzheimer's disease. <b>2013</b> , 2, 1119-24		36
1208	Elevated CSF Tau is associated with psychosis in Alzheimer's disease. <b>2013</b> , 170, 1212-3		20
1207	Clinical, biological, and imaging features of monogenic Alzheimer's Disease. <b>2013</b> , 2013, 689591		17
1206	Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. <b>2013</b> , 207, 1703-12		120
1205	Plasma proteomics for the identification of Alzheimer disease. <b>2013</b> , 27, 337-42		36
1204	Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission. <b>2013</b> , 169, 211-5		7
1203	Biomarkers in Alzheimer's disease with a special emphasis on event-related oscillatory responses. <b>2013</b> , 62, 237-73		52
1202	Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer's disease pathogenic factor. <b>2014</b> , 19, 051205		29
1201	Studies on Alzheimer's Disease. <b>2013</b> ,		

1200	Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers. <b>2013</b> , 14, 1310-22	121
1199	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. <b>2013</b> , 26, 276-82	19
1198	Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimer's disease pathology. <b>2013</b> , 36, 321-34	27
1197	Identification of an important potential confound in CSF AD studies: aliquot volume. <b>2013</b> , 51, 2311-7	36
1196	$\beta$ -secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF A $\beta$ <b>2013</b> , 37, 1714-25	16
1195	Motor protein based tau protein detection device. <b>2013</b> ,	
1194	Cerebrospinal fluid levels of phosphorylated tau and A $\beta$ 1-38/A $\beta$ 1-40/A $\beta$ 1-42 in Alzheimer's disease with PS1 mutations. <b>2013</b> , 20, 107-12	17
1193	Semagacestat's fall: where next for AD therapies?. <b>2013</b> , 19, 1214-5	17
1192	Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. <b>2013</b> , 3, e233	167
1191	CSF protein biomarkers predicting longitudinal reduction of CSF $\beta$ -amyloid42 in cognitively healthy elders. <b>2013</b> , 3, e293	37
1190	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. <i>Neurology</i> , <b>2013</b> , 80, 1784-91	6.5 175
1189	A blood gene expression marker of early Alzheimer's disease. <b>2013</b> , 33, 737-53	60
1188	Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia?. <b>2013</b> , 36, 57-66	70
1187	Overview of Parkinson's disease: epidemiology, diagnosis, course, medical and surgical management. 1-13	
1186	Parkinson's disease: pathology, anatomy, and behavior. 14-24	
1185	Cognitive assessment in Parkinson's disease. 53-64	
1184	Diagnosis and biomarkers: CSF. 97-108	
1183	A new sandwich immunoassay for detection of the $\beta$ -secretase cleaved, soluble amyloid- $\beta$ protein precursor in cerebrospinal fluid and serum. <b>2013</b> , 37, 667-78	9

1182	Cerebrospinal fluid biomarkers mirror rate of cognitive decline. <b>2013</b> , 34, 949-56		30
1181	The amyloid- $\beta$ oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. <b>2013</b> , 34, 985-94		54
1180	Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. <b>2013</b> , 5, 47		31
1179	Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. <b>2013</b> , 34, 297-305		42
1178	Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid- $\beta$ and tau. <i>Frontiers in Aging Neuroscience</i> , <b>2013</b> , 5, 55	5:3	95
1177	Cerebrospinal fluid A $\beta$ 1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. <b>2013</b> , 36, 759-67		65
1176	Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease. <b>2013</b> , 35, 284-94		14
1175	Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. <b>2013</b> , 18, 1150-73		15
1174	The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?. <b>2013</b> , 8, 70-8		3
1173	Amyloid pathology influences a $\beta$ 1-42 cerebrospinal fluid levels in dementia with lewy bodies. <b>2013</b> , 35, 137-46		42
1172	Frontal presentation of Alzheimer's disease: a series of patients with biological evidence by CSF biomarkers. <b>2013</b> , 7, 66-74		21
1171	Low CSF levels of both $\beta$ synuclein and the $\beta$ synuclein cleaving enzyme neurosin in patients with synucleinopathy. <b>2013</b> , 8, e53250		102
1170	Direct detection of alternative open reading frames translation products in human significantly expands the proteome. <b>2013</b> , 8, e70698		135
1169	The diagnostic value of CSF $\beta$ synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. <b>2013</b> , 8, e81654		47
1168	Effects of baseline CSF $\beta$ synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. <b>2013</b> , 8, e85443		11
1167	Abnormal platelet amyloid- $\beta$ protein precursor (A $\beta$ PP) metabolism in Alzheimer's disease: identification and characterization of a new A $\beta$ PP isoform as potential biomarker. <b>2013</b> , 35, 285-95		15
1166	Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. <i>Frontiers in Aging Neuroscience</i> , <b>2013</b> , 5, 25	5:3	11
1165	Neuropeptide Kyotorphin (Tyrosyl-Arginine) has Decreased Levels in the Cerebro-Spinal Fluid of Alzheimer's Disease Patients: Potential Diagnostic and Pharmacological Implications. <i>Frontiers in Aging Neuroscience</i> , <b>2013</b> , 5, 68	5:3	10

1164	Oxidative Stress and Its Clinical Applications in Dementia. <b>2013</b> , 2013, 319898		25
1163	Candidate Bio-Markers of Alzheimer's Disease. <b>2013</b> ,		1
1162	Differences in routine clinical practice between early and late onset Alzheimer's disease: data from the Swedish Dementia Registry (SveDem). <b>2014</b> , 41, 411-9		20
1161	Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. <b>2014</b> , 9, e116081		70
1160	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. <b>2014</b> , 2014, 1-14		11
1159	Proteomic analysis of serum proteins in triple transgenic Alzheimer's disease mice: implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early Alzheimer's disease. <b>2014</b> , 40, 575-86		9
1158	Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 47	5-3	74
1157	Amyloid Beta1-42 and the Phosphorylated Tau Threonine 231 in Brains of Aged Cynomolgus Monkeys ( <i>Macaca fascicularis</i> ). <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 313	5-3	17
1156	Carnosinases, their substrates and diseases. <b>2014</b> , 19, 2299-329		49
1155	Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers?. <b>2014</b> , 13, 173-86		14
1154	Biological markers of Alzheimer's disease. <b>2014</b> , 72, 227-31		14
1153	Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. <b>2014</b> , 4, 385-94		24
1152	Alzheimer biomarkers and clinical Alzheimer disease were not associated with increased cerebrovascular disease in a memory clinic population. <b>2014</b> , 11, 40-6		4
1151	Biomarkers for predicting cognitive decline in those with normal cognition. <b>2014</b> , 40, 587-94		27
1150	The role of extracellular matrix in plasticity in the spinal cord. 155-165		
1149	Noninvasive brain stimulation in cognitive rehabilitation: guiding plasticity after injury to the central nervous system. 218-239		
1148	β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ-X peptides through alternative amyloid precursor protein cleavage. <b>2014</b> , 6, 75		28
1147	Antibody-derived in vivo imaging of tau pathology. <b>2014</b> , 34, 16835-50		42

1146	[Clinically validated molecular biomarkers of neurodegenerative dementia]. <b>2014</b> , 85, 1372-81	4
1145	Biomarkers in biological fluids for dementia with Lewy bodies. <b>2014</b> , 6, 72	24
1144	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. <b>2014</b> , 4, e419	32
1143	Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians. <b>2014</b> , 4, 363-78	15
1142	Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. <b>2014</b> , 55, 347-65	28
1141	Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. <b>2014</b> , 15, 7865-82	39
1140	Metabolomics in the Study of Alzheimer's Disease. <b>2014</b> , 64, 249-278	1
1139	Plasma-Enabled Carbon Nanostructures for Early Diagnosis of Neurodegenerative Diseases. <b>2014</b> , 7, 4896-4929	8
1138	Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. <b>2014</b> , 85, 1065-75	63
1137	Candidate biomarkers of multiple system atrophy in cerebrospinal fluid. <b>2014</b> , 25, 653-62	6
1136	HSV-1 and Alzheimer's disease: more than a hypothesis. <b>2014</b> , 5, 97	68
1135	MicroRNA-384 regulates both amyloid precursor protein and $\beta$ -secretase expression and is a potential biomarker for Alzheimer's disease. <b>2014</b> , 34, 160-6	68
1134	MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease. <b>2014</b> , 10, 2395-400	109
1133	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. <b>2014</b> , 4, 297-304	63
1132	Amyloid- $\beta$ efflux from the central nervous system into the plasma. <b>2014</b> , 76, 837-44	151
1131	Narcolepsy is a common phenotype in HSAN IE and ADCA-DN. <b>2014</b> , 137, 1643-55	36
1130	A data-driven model of biomarker changes in sporadic Alzheimer's disease. <b>2014</b> , 137, 2564-77	149
1129	Platelet $\alpha$ IIb $\beta$ 3 integrin and metalloproteinase 10 expression correlates with clock drawing test scores in Alzheimer's disease. <b>2014</b> , 29, 414-20	21

1128	Therapeutic strategies to prevent Alzheimer's disease pathogenesis using a fluorescent conjugated polyelectrolyte. <b>2014</b> , 14, 508-14	13
1127	Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration. <b>2014</b> , 13, 4518-25	28
1126	Electroanalytical Sensors and Methods for Assays and Studies of Neurological Biomarkers. <b>2014</b> , 26, 1236-1248	6
1125	Reduced $\beta$ -synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. <b>2014</b> , 21, 388-94	50
1124	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <b>2014</b> , 1, 534-43	78
1123	Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. <b>2014</b> , 275, 428-36	94
1122	Surface plasmon resonance: advances of label-free approaches in the analysis of biological samples. <b>2014</b> , 6, 3325-36	12
1121	Accelerating cortical thinning: unique to dementia or universal in aging?. <b>2014</b> , 24, 919-34	187
1120	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. <b>2014</b> , 6, 226ra30	244
1119	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <b>2014</b> , 9, 53	150
1118	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <b>2014</b> , 6, 38	31
1117	Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. <b>2014</b> , 6, 41	30
1116	Linking hypothetical knowledge patterns to disease molecular signatures for biomarker discovery in Alzheimer's disease. <b>2014</b> , 6, 97	6
1115	Imaging endpoints for clinical trials in Alzheimer's disease. <b>2014</b> , 6, 87	40
1114	A candidate plasma protein classifier to identify Alzheimer's disease. <b>2015</b> , 43, 549-63	31
1113	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid $\beta$ -amyloid 42: a cross-validation study against amyloid positron emission tomography. <b>2014</b> , 71, 1282-9	254
1112	Plasma $\beta$ -amyloid and MRI markers of cerebral small vessel disease: Three-City Dijon study. <i>Neurology</i> , <b>2014</b> , 83, 2038-45	6.5 16
1111	Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. <b>2014</b> , 71, 1183-91	65

1110	Synthesis aided structural determination of amyloid- $\beta$ (1-15) glycopeptides, new biomarkers for Alzheimer's disease. <b>2014</b> , 50, 15067-70	11
1109	Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. <b>2014</b> , 71, 476-83	125
1108	Unregulated Lipid Peroxidation in Neurological Dysfunction. <b>2014</b> , 31-55	1
1107	Emerging $\beta$ -amyloid pathology and accelerated cortical atrophy. <b>2014</b> , 71, 725-34	43
1106	Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. <b>2014</b> , 41, 877-86	21
1105	High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease. <b>2014</b> , 37, 196-206	23
1104	The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. <b>2014</b> , 1842, 1219-31	411
1103	Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. <b>2014</b> , 89, 607-14	14
1102	Detection of misfolded A $\beta$ oligomers for sensitive biochemical diagnosis of Alzheimer's disease. <b>2014</b> , 7, 261-8	124
1101	The amyloid- $\beta$ degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease. <b>2014</b> , 573, 7-12	48
1100	Diagnosticare la malattia di Alzheimer. <b>2014</b> , 14, 1-14	
1099	The future of blood-based biomarkers for Alzheimer's disease. <b>2014</b> , 10, 115-31	196
1098	Biomarkers in amyloid- $\beta$ immunotherapy trials in Alzheimer's disease. <b>2014</b> , 39, 189-201	54
1097	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. <b>2014</b> , 261, 144-51	45
1096	The pivotal role of copper(II) in the enantio-recognition of tryptophan and histidine by gold nanoparticles. <b>2014</b> , 406, 481-91	12
1095	Plasma phospholipids identify antecedent memory impairment in older adults. <b>2014</b> , 20, 415-8	706
1094	Converging on neurodegenerative mechanisms. <b>2014</b> , 46, 317	
1093	Huntington disease: natural history, biomarkers and prospects for therapeutics. <i>Nature Reviews Neurology</i> , <b>2014</b> , 10, 204-16	15 600

1092	Electroanalytical and surface plasmon resonance sensors for detection of breast cancer and Alzheimer's disease biomarkers in cells and body fluids. <b>2014</b> , 139, 1814-25	39
1091	Neurodegenerative Diseases. <b>2014</b> ,	2
1090	Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors. <b>2014</b> , 118, 225-238	23
1089	Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. <b>2014</b> , 106, 191-204	172
1088	Dementia in Clinical Practice: A Neurological Perspective. <b>2014</b> ,	20
1087	What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. <b>2014</b> , 117, 20-40	412
1086	Fungal infection in patients with Alzheimer's disease. <b>2014</b> , 41, 301-11	97
1085	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <b>2014</b> , 13, 614-29	1985
1084	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <b>2014</b> , 261, 1234-43	29
1083	Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease. <b>2014</b> , 16, 150-60	65
1082	Early identification and heritability of mild cognitive impairment. <b>2014</b> , 43, 600-10	43
1081	CSF A $\beta$ 1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. <b>2014</b> , 10, 381-92	53
1080	Do CSF levels of t-Tau, p-Tau and A $\beta$ 1-42 correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A [11C]-FP-CIT study in the early stages of the disease. <b>2014</b> , 41, 2137-43	8
1079	Biomarker time out. <b>2014</b> , 20, 1560-3	2
1078	CSF A $\beta$ 42 predicts early-onset dementia in Parkinson disease. <i>Neurology</i> , <b>2014</b> , 82, 1784-90	6.5 108
1077	Retina: source of the earliest biomarkers for Alzheimer's disease?. <b>2014</b> , 40, 237-43	26
1076	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <b>2014</b> , 85, 684-91	47
1075	Who needs cerebrospinal biomarkers? A national survey in clinical practice. <b>2014</b> , 40, 857-61	20



1074	Trace vapour detection at room temperature using Raman spectroscopy. <b>2014</b> , 139, 1960-6	7
1073	Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid- $\beta$ in cerebrospinal fluid. <b>2014</b> , 60, 987-94	109
1072	CSF in Alzheimer's disease. <b>2014</b> , 65, 143-72	18
1071	Occupational exposure to aluminum and its amyloidogenic link with cognitive functions. <b>2014</b> , 139, 57-64	29
1070	Functional and Structural MRI in Alzheimer's Disease: A Multimodal Approach. <b>2014</b> , 371-422	
1069	Detection and quantification of plasma amyloid- $\beta$ by selected reaction monitoring mass spectrometry. <b>2014</b> , 840, 1-9	27
1068	Disruption of behavioral circadian rhythms induced by psychophysiological stress affects plasma free amino acid profiles without affecting peripheral clock gene expression in mice. <b>2014</b> , 450, 880-4	16
1067	Vitamin D in relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes. <b>2014</b> , 69, 1132-8	54
1066	Cerebrospinal fluid $\beta$ -synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease. <b>2015</b> , 43, 1007-16	25
1065	MicroRNA-135a and -200b, potential Biomarkers for Alzheimer's disease, regulate $\beta$ -secretase and amyloid precursor protein. <b>2014</b> , 1583, 55-64	68
1064	Direct analytical sample quality assessment for biomarker investigation: qualifying cerebrospinal fluid samples. <b>2014</b> , 14, 1954-62	17
1063	Estimation of electrokinetic and hydrodynamic global properties of relevant amyloid-beta peptides through the modeling of their effective electrophoretic mobilities and analysis of their propensities to aggregation. <b>2014</b> , 37, 2618-24	4
1062	The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. <b>2014</b> , 261, 1187-95	9
1061	Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. <b>2014</b> , 14, 472	33
1060	Altered cerebrospinal fluid levels of amyloid $\beta$ and amyloid precursor-like protein 1 peptides in Down's syndrome. <b>2014</b> , 16, 510-6	26
1059	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. <b>2014</b> , 14, 64	34
1058	Distinct transthyretin oxidation isoform profile in spinal fluid from patients with Alzheimer's disease and mild cognitive impairment. <b>2014</b> , 11, 12	15
1057	MRI in Psychiatry. <b>2014</b> ,	2

1056	The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy. <b>2014</b> , 18, 78-85	9
1055	Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. <b>2014</b> , 20, 8-15	30
1054	Increased CSF $\beta$ -synuclein levels in Alzheimer's disease: correlation with tau levels. <b>2014</b> , 10, S290-8	54
1053	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. <b>2014</b> , 35, 614-22	36
1052	New insights on Alzheimer's disease. <b>2014</b> , 2, 57	5
1051	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. <b>2014</b> , 88, 426-49	84
1050	Role of HIV in amyloid metabolism. <b>2014</b> , 9, 483-91	43
1049	Levels of cerebrospinal fluid $\beta$ -synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. <b>2014</b> , 6, 25	130
1048	The critical need for defining preclinical biomarkers in Alzheimer's disease. <b>2014</b> , 10, S196-212	89
1047	Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. <b>2014</b> , 217, 143-6	32
1046	Progress update: fluid and imaging biomarkers in Alzheimer's disease. <b>2014</b> , 75, 520-6	18
1045	Can a novel computerized cognitive screening test provide additional information for early detection of Alzheimer's disease?. <b>2014</b> , 10, 790-8	51
1044	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <b>2014</b> , 10, 53-61	84
1043	Beyond statistics: a new combinatorial approach to identifying biomarker panels for the early detection and diagnosis of Alzheimer's disease. <b>2014</b> , 39, 211-7	3
1042	Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 187	5-3 49
1041	Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. <b>2014</b> , 4, 335-43	25
1040	Conventional brain imaging of white matter lesions. 117-128	
1039	A novel PSEN1 mutation in a patient with sporadic early-onset Alzheimer's disease and prominent cerebellar ataxia. <b>2014</b> , 41, 709-14	7

1038	Cerebral small vessel disease: cerebrospinal fluid aspects. 200-216	
1037	Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies. <b>2014</b> , 7, 1-7	23
1036	Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. <b>2015</b> , 43, 1393-402	20
1035	Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer's disease and other neurodegenerative diseases. <b>2015</b> , 8, 137-143	23
1034	Alzheimer's disease. <b>2015</b> , 1, 15056	755
1033	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid- $\beta$ Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <b>2015</b> , 48, 175-87	38
1032	Common Variants in PLD3 and Correlation to Amyloid-Related Phenotypes in Alzheimer's Disease. <b>2015</b> , 46, 491-5	15
1031	Increased cerebrospinal fluid fibrinogen in major depressive disorder. <b>2015</b> , 5, 11412	35
1030	Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. <b>2015</b> , 46, 817-36	37
1029	Amyloid- $\beta$ and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. <b>2015</b> , 46, 261-9	29
1028	Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function. <b>2015</b> , 44, 1313-22	19
1027	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <b>2015</b> , 48 Suppl 1, S63-86	253
1026	Peripheral Defensins 1 and 2 are elevated in Alzheimer's disease. <b>2015</b> , 44, 1131-43	13
1025	Investigation of neurodegenerative diseases from body fluid samples using Fourier transform infrared spectroscopy. <b>2015</b> , 4, 341-357	9
1024	Proteomic Analysis of Protein Expression Throughout Disease Progression in a Mouse Model of Alzheimer's Disease. <b>2015</b> , 47, 915-26	14
1023	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <b>2015</b> , 48 Suppl 1, S171-91	29
1022	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid- $\beta$ Levels in Patients with Alzheimer's Disease?. <b>2015</b> , 47, 1069-78	21
1021	Biomarkers in Sporadic and Familial Alzheimer's Disease. <b>2015</b> , 47, 291-317	61

1020	Increased CSF A $\beta$ during the very early phase of cerebral A $\beta$ deposition in mouse models. <b>2015</b> , 7, 895-903		29
1019	Cerebrospinal Fluid from Alzheimer's Disease Patients Contains Fungal Proteins and DNA. <b>2015</b> , 47, 873-6		22
1018	Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool for Alzheimer's Disease Diagnostics. <b>2015</b> , 46, 1007-20		9
1017	How Preserved is Emotion Recognition in Alzheimer Disease Compared With Behavioral Variant Frontotemporal Dementia?. <b>2015</b> , 29, 154-7		42
1016	Do cerebrospinal fluid transfer methods affect measured amyloid $\beta$ 42, total tau, and phosphorylated tau in clinical practice?. <b>2015</b> , 1, 380-4		4
1015	Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with A $\beta$ 42 and influence of disease on the total-A $\beta$ 42/A $\beta$ 40 ratio. <b>2015</b> , 135, 1049-58		14
1014	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. <b>2015</b> , 7, 74		86
1013	Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?. <b>2015</b> , 47, 815-43		58
1012	Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments. <b>2015</b> , 28, 402-9		28
1011	A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease. <i>Journal of Clinical Neurology (Korea)</i> , <b>2015</b> , 11, 132-41	1.7	13
1010	Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer's Mice and in Human Patients. <b>2015</b> , 12, 752-60		29
1009	Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 125	4.1	13
1008	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 138	4.1	38
1007	Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 142	4.1	18
1006	Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 143	4.1	18
1005	Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 168	4.1	10
1004	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 179	4.1	223
1003	Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 181	4.1	34

1002	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 186	4.1	19
1001	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 202	4.1	16
1000	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 216	4.1	31
999	Synaptic activity and Alzheimer's disease: a critical update. <b>2015</b> , 9, 423		74
998	Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls. <b>2015</b> , 10, e0127100		21
997	Influence of Allergy on Immunoglobulins and Amyloid- $\beta$ in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. <b>2015</b> , 48, 495-505		6
996	Recent Progress in the Identification of Non-Invasive Biomarkers to Support the Diagnosis of Alzheimer's Disease in Clinical Practice and to Assist Human Clinical Trials. <b>2015</b> ,		0
995	Alterations in cholesterol and ganglioside GM1 content of lipid rafts in platelets from patients with Alzheimer disease. <b>2015</b> , 29, 63-9		15
994	Hybrid Graphene Oxide Based Plasmonic-Magnetic Multifunctional Nanoplatform for Selective Separation and Label-Free Identification of Alzheimer's Disease Biomarkers. <b>2015</b> , 7, 13693-700		94
993	Platelet dysfunction in hypercholesterolemia mice, two Alzheimer's disease mouse models and in human patients with Alzheimer's disease. <b>2015</b> , 16, 543-58		11
992	Circulating Biomarker Panels in Alzheimer's Disease. <b>2015</b> , 61, 497-503		29
991	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <b>2015</b> , 11, 549-60		159
990	Preanalytical variables and Alzheimer disease biomarker concentrations in cerebrospinal fluid. <b>2015</b> , 61, 686-8		1
989	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <b>2015</b> , 10, 64		87
988	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. <b>2015</b> , 1, 412-9		66
987	Biomarker discovery, high performance and cloud computing: A comprehensive review. <b>2015</b> ,		2
986	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. <b>2015</b> , 1854, 757-68		18
985	Independent information from cerebrospinal fluid amyloid- $\beta$ and florbetapir imaging in Alzheimer's disease. <b>2015</b> , 138, 772-83		169

984	Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria. <b>2015</b> , 449, 3-8	22
983	Binding and Dissociation of Biomarkers for Alzheimer's Disease on Biosensor Surfaces. <b>2015</b> , 377-486	
982	Fluid markers of traumatic brain injury. <b>2015</b> , 66, 99-102	35
981	An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. <b>2015</b> , 14, 654-63	65
980	Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India. <b>2015</b> , 13, 44-7	3
979	Cerebrospinal Fluid in Clinical Neurology. <b>2015</b> ,	13
978	Diagnostic Accuracy of Cerebrospinal Fluid Amyloid- $\beta$ Isoforms for Early and Differential Dementia Diagnosis. <b>2015</b> , 45, 813-22	75
977	Neuroproteomics tools in clinical practice. <b>2015</b> , 1854, 705-17	25
976	Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. <b>2015</b> , 9, 715-31	80
975	CSF and plasma amyloid- $\beta$ temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury. <b>2014</b> , 4, 6446	60
974	Advances in Salivary Diagnostics. <b>2015</b> ,	8
973	Label-free detection of Alzheimer's disease through the ADP3 peptoid recognizing the serum amyloid-beta42 peptide. <b>2015</b> , 51, 718-21	33
972	Liquid biopsies in patients with diffuse glioma. <b>2015</b> , 129, 849-65	62
971	Understanding biomarkers of neurodegeneration: Novel approaches to detecting tau pathology. <b>2015</b> , 21, 219-20	14
970	Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. <b>2015</b> , 21, 217-9	52
969	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <b>2015</b> , 11, 1180-90	201
968	Plasma and cerebrospinal fluid amyloid- $\beta$ levels in late-life depression: A systematic review and meta-analysis. <b>2015</b> , 69, 35-41	42
967	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <b>2015</b> , 36, 2340-7	40

966	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. <b>2015</b> , 40, 151-61		54
965	Cerebrospinal fluid tau and amyloid- $\beta$ 1-42 in patients with dementia. <b>2015</b> , 138, 2716-31		105
964	Amyloid- $\beta$ as a biomarker for Alzheimer's disease: quantification methods in body fluids. <b>2015</b> , 12, 343-54		18
963	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. <b>2015</b> , 449, 9-15		51
962	Top-down and bottom-up lipidomic analysis of rabbit lipoproteins under different metabolic conditions using flow field-flow fractionation, nanoflow liquid chromatography and mass spectrometry. <b>2015</b> , 1405, 140-8		14
961	Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials. <b>2015</b> , 29, 487-502		22
960	Clearance systems in the brain-implications for Alzheimer disease. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 457-70	15	759
959	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. <i>Neurology</i> , <b>2015</b> , 85, 626-33	6.5	107
958	d-serine levels in Alzheimer's disease: implications for novel biomarker development. <b>2015</b> , 5, e561		120
957	Hippocampal atrophy varies by neuropsychologically defined MCI among men in their 50s. <b>2015</b> , 23, 456-65		14
956	Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease. <b>2015</b> , 1, 67-74		4
955	[Novel methods for dementia diagnostics]. <b>2015</b> , 86, 452-60		4
954	New criteria for Alzheimer's disease: which, when and why?. <b>2015</b> , 138, 1134-7		9
953	Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease. <b>2015</b> , 15, 8		1
952	Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases. <b>2015</b> , 15, 50		2
951	Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. <b>2015</b> , 10, 14		31
950	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 1: general aspects and paradigmatic discussion of depressive disorders. <b>2015</b> , 265, 5-18		19
949	Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. <b>2015</b> , 35, 1055-68		74

948	Blood protein predictors of brain amyloid for enrichment in clinical trials?. <b>2015</b> , 1, 48-60		37
947	The neuropsychiatric examination of the young-onset dementias. <b>2015</b> , 38, 249-64		19
946	Predicting Reduction of Cerebrospinal Fluid $\beta$ -Amyloid 42 in Cognitively Healthy Controls. <b>2015</b> , 72, 554-60		39
945	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. <b>2015</b> , 125, 1979-86		144
944	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <b>2015</b> , 11, 1306-15		87
943	Amyloid biomarkers in Alzheimer's disease. <b>2015</b> , 36, 297-309		320
942	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. <b>2015</b> , 262, 2722-30		34
941	MR spectroscopy, a new in vivo biomarker for dementia disorders?. <b>2015</b> , 86, 1284-5		2
940	Multiple function fluorescein probe performs metal chelation, disaggregation, and modulation of aggregated A $\beta$ and A $\beta$ -Cu complex. <b>2015</b> , 6, 1880-91		30
939	Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , <b>2015</b> , 85, 1834-42	6.5	75
938	Cerebrospinal fluid A $\beta$ 40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. <b>2015</b> , 358, 308-16		20
937	The relationship between CSF tau markers, hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. <b>2015</b> , 1, 81-86		4
936	Translational nanomedicine--through the therapeutic window. <b>2015</b> , 10, 3249-60		5
935	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. <b>2015</b> , 7, 40		90
934	Developing a molecular taxonomy for traumatic brain injury: a perspective to enable the development of diagnostics and therapeutics. <b>2015</b> , 9, 619-21		3
933	Hippocampal complex atrophy in poststroke and mild cognitive impairment. <b>2015</b> , 35, 1729-37		15
932	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , <b>2015</b> , 85, 1240-9	6.5	192
931	The impact of Tween 20 on repeatability of amyloid $\beta$ and tau measurements in cerebrospinal fluid. <b>2015</b> , 53, e329-32		4



930	Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer's disease in patients with the apolipoprotein E ɛ4 genotype. <b>2015</b> , 20, 84-8	25
929	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <b>2015</b> , 138, 3373-85	165
928	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 41-55	15 116
927	Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. <b>2015</b> , 44, 525-39	49
926	Plasma-enabled sustainable elemental lifecycles: honeycomb-derived graphenes for next-generation biosensors and supercapacitors. <b>2015</b> , 17, 2164-2171	34
925	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. <b>2015</b> ,	13
924	Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. <b>2015</b> , 36, 149-56	12
923	Binding of human proteins to amyloid-β protofibrils. <b>2015</b> , 10, 766-74	16
922	Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms. <b>2015</b> , 32, 1294-300	80
921	Raman spectroscopy of blood serum for Alzheimer's disease diagnostics: specificity relative to other types of dementia. <b>2015</b> , 8, 584-96	86
920	Statistically quantified measurement of an Alzheimer's marker by surface-enhanced Raman scattering. <b>2015</b> , 8, 567-74	29
919	Global properties and propensity to dimerization of the amyloid-beta (12-28) peptide fragment through the modeling of its monomer and dimer diffusion coefficients and electrophoretic mobilities. <b>2015</b> , 36, 805-12	4
918	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <b>2015</b> , 11, 455-61	7
917	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <b>2015</b> , 11, 58-69	271
916	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences Part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <b>2015</b> , 265, 87-106	19
915	Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. <b>2015</b> , 20, 1188-96	220
914	Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. <b>2015</b> , 438, 67-9	15
913	Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. <b>2015</b> , 19, 154-63	34

912	Autophagic Flux Failure in Neurodegeneration: Identifying the Defect and Compensating Flux Offset. <b>2016</b> ,	2
911	Overview of Alzheimer's disease. <b>2016</b> ,	
910	Seeing Early Signs of Alzheimer's Disease Through the Lens of the Eye. <b>2017</b> , 14, 6-17	9
909	Blood-based Amyloid and Tau Biomarker Tests For Alzheimer's Disease. <b>2016</b> , 4, 4-13	
908	Exploring Biomarkers for Alzheimer's Disease. <b>2016</b> , 10, KE01-6	31
907	Proteomic Biomarkers in Alzheimer's disease. <b>2016</b> , 01,	2
906	Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid A $\beta$ 42 and the Ratios of A $\beta$ Isoforms Using Low Protein Binding Tubes. <b>2016</b> , 53, 1121-32	43
905	Amyloid precursor protein in peripheral granulocytes as a potential biomarker for Alzheimer's disease. <b>2016</b> , 11, S92-S97	2
904	Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay. <b>2016</b> , 10, 8	16
903	Low Cerebrospinal Fluid Amyloid-Beta Concentration Is Associated with Poorer Delayed Memory Recall in Women. <b>2016</b> , 6, 303-12	8
902	Grey and White Matter Clinico-Anatomical Correlates of Disinhibition in Neurodegenerative Disease. <b>2016</b> , 11, e0164122	10
901	Methods for the Specific Detection and Quantitation of Amyloid- $\beta$ Oligomers in Cerebrospinal Fluid. <b>2016</b> , 53, 53-67	21
900	Early Detection of Amyloidopathy in Alzheimer's Mice by Hyperspectral Endoscopy. <b>2016</b> , 57, 3231-8	42
899	Plasma Biomarkers in Alzheimer's Disease. <b>2016</b> ,	1
898	Femtomolar Detection of Tau Proteins in Undiluted Plasma Using Surface Plasmon Resonance. <b>2016</b> , 88, 7793-9	48
897	Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction. <b>2016</b> , 124, 353-61	73
896	Update on fluid biomarkers for concussion. <b>2016</b> , 1, CNC12	4
895	Charge regulation phenomenon predicted from the modeling of polypeptide electrophoretic mobilities as a relevant mechanism of amyloid-beta peptide oligomerization. <b>2016</b> , 37, 711-8	1

894	Current status of biomarker research in neurology. <b>2016</b> , 7, 14	22
893	Cerebral white matter lesions - associations with A $\beta$ isoforms and amyloid PET. <b>2016</b> , 6, 20709	41
892	A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. <b>2016</b> , 54, 383-95	31
891	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <b>2017</b> , 55, 159-170	19
890	Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. <b>2016</b> , 54, 615-33	18
889	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <b>2017</b> , 55, 19-35	29
888	Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease. <b>2016</b> , 52, 1055-64	6
887	sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <b>2016</b> , 8, 466-76	256
886	Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. <b>2017</b> , 55, 303-313	24
885	PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease. <b>2016</b> , 53, 1563-76	18
884	Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. <b>2016</b> , 16, 217	9
883	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <b>2016</b> , 8, 41	78
882	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. <b>2016</b> , 51, 227-36	10
881	What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?. <b>2016</b> , 51, 793-800	7
880	Cerebrospinal Fluid Biomarkers for Huntington's Disease. <b>2016</b> , 5, 1-13	39
879	Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease. <b>2016</b> , 51, 1085-97	10
878	Estandarizaci3n de aspectos preanal3ticos para el estudio de biomarcadores de la enfermedad de Alzheimer en el l3quido cefalorraqu3deo. <b>2016</b> , 9, 184-188	
877	Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. <b>2016</b> , 52, 1403-13	11

876	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. <b>2017</b> , 55, 585-595		30
875	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. <b>2016</b> , 54, 55-67		22
874	Conversion from MCI to AD in patients with the APOE $\epsilon$ genotype: Prediction by plasma HCY and serum BDNF. <b>2016</b> , 626, 19-24		16
873	References. <b>2016</b> , 353-428		
872	Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. <b>2016</b> , 3, 51-62		38
871	Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. <i>Neurology</i> , <b>2016</b> , 86, 1754-61	6.5	48
870	CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. <b>2016</b> , 15, 673-684		979
869	Evaluation of DSM-5 and IWG-2 criteria for the diagnosis of Alzheimer's disease and dementia with Lewy bodies. <b>2016</b> , 3, 9-12		2
868	Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. <b>2016</b> , 299, 112-117		30
867	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. <b>2016</b> , 10, 1242-1253		40
866	Diagnostic de la maladie d'Alzheimer : apport de l'imagerie au florbtapir et autres radiopharmaceutiques de la plaque amyloïde. <b>2016</b> , 40, 364-381		2
865	Plasma tau in Alzheimer disease. <i>Neurology</i> , <b>2016</b> , 87, 1827-1835	6.5	269
864	Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. <b>2016</b> , 80, 355-67		67
863	Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms - A critical review. <b>2016</b> , 940, 21-37		36
862	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. <b>2016</b> , 39, 117-23		7
861	Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. <b>2016</b> , 3, 12-20		115
860	Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. <b>2016</b> , 18, 63-70		21
859	Reference measurement procedure for CSF amyloid beta (A $\beta$ ) and the CSF A $\beta$ /A $\beta$ ratio - a cross-validation study against amyloid PET. <b>2016</b> , 139, 651-658		56

858	Alzheimer's Disease Cerebrospinal Fluid (CSF) Biomarkers. <b>2016</b> , 139-180		3
857	Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. <b>2016</b> , 123, 1443-1447		31
856	Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid. <b>2016</b> , 75, 918-924		34
855	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <b>2016</b> , 54, 287-95		50
854	Molecular imaging in the diagnosis of Alzheimer's disease and related disorders. <b>2016</b> , 172, 725-734		17
853	Plasma $\beta$ -amyloid in Alzheimer's disease and vascular disease. <b>2016</b> , 6, 26801		290
852	Fluid biomarkers for mild traumatic brain injury and related conditions. <i>Nature Reviews Neurology</i> , <b>2016</b> , 12, 563-74	15	150
851	Magnetic Resonance Imaging of Vascular Contributions to Cognitive Impairment and Dementia. <b>2016</b> , 60, 349-353		5
850	Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals. <b>2016</b> , 10, 1225-1241		23
849	Traumatic brain injuries. <b>2016</b> , 2, 16084		245
848	Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting. <b>2016</b> , 8, 2497-2518		15
847	Increased amyloidogenic APP processing in APOE e4-negative individuals with cerebral $\beta$ -amyloidosis. <b>2016</b> , 7, 10918		39
846	Emerging understanding of the protein corona at the nano-bio interfaces. <b>2016</b> , 11, 817-832		171
845	Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. <b>2016</b> , 7, 11934		547
844	Early diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level. <b>2016</b> , 6, 20364		36
843	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. <b>2016</b> , 6, 283-94		23
842	Impact of frequent cerebrospinal fluid sampling on A $\beta$ levels: systematic approach to elucidate influencing factors. <b>2016</b> , 8, 21		10
841	High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. <b>2016</b> , 8, 22		26

840	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. <b>2016</b> , 8, 27	12
839	Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice. <b>2016</b> , 31, 836-47	38
838	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. <b>2016</b> , 23, 796-806	35
837	Fluid Biomarkers and Diagnostics. <b>2016</b> , 565-587	
836	Prospects and Challenges for Alzheimer Therapeutics. <b>2016</b> , 605-637	0
835	Clinical proteomics of enervated neurons. <b>2016</b> , 13, 10	2
834	Cerebrospinal fluid ratios with A $\beta$ 42 predict preclinical brain $\beta$ -amyloid accumulation. <b>2016</b> , 2, 27-38	35
833	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. <b>2016</b> , 13, 4	18
832	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <b>2016</b> , 11, 3	168
831	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , <b>2016</b> , 86, 829-35	6.5 135
830	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <b>2016</b> , 12, 292-323	832
829	CSF A $\beta$ 42/A $\beta$ 40 and A $\beta$ 42/A $\beta$ 8 ratios: better diagnostic markers of Alzheimer disease. <b>2016</b> , 3, 154-65	244
828	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <b>2016</b> , 139 Suppl 1, 290-317	45
827	CSF biomarkers in neurodegenerative and vascular dementias. <b>2016</b> , 138-140, 36-53	27
826	CACNA1C polymorphism and altered phosphorylation of tau in bipolar disorder. <b>2016</b> , 208, 195-6	10
825	Symptomatic and preclinical Alzheimer's disease: Neuropathology and imaging. <b>2016</b> , 22, 127-131	1
824	Alzheimer's disease. <b>2016</b> , 388, 505-17	1720
823	Insulin-degrading enzyme secretion from astrocytes is mediated by an autophagy-based unconventional secretory pathway in Alzheimer disease. <b>2016</b> , 12, 784-800	71

822	Time-Dependent Increase of Chitinase1 in APP/PS1 Double Transgenic Mice. <b>2016</b> , 41, 1604-11	10
821	Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. <b>2016</b> , 93, 1-5	11
820	Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. <b>2016</b> , 91, 1-9	59
819	Magnetic resonance imaging as a potential biomarker for Parkinson's disease. <b>2016</b> , 175, 4-16	16
818	Round robin test on quantification of amyloid- $\beta$ 1-42 in cerebrospinal fluid by mass spectrometry. <b>2016</b> , 12, 55-9	38
817	Plasma Proteomics Biomarkers in Alzheimer's Disease: Latest Advances and Challenges. <b>2016</b> , 1303, 521-9	10
816	Assessing the commutability of reference material formats for the harmonization of amyloid- $\beta$ measurements. <b>2016</b> , 54, 1177-91	48
815	Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease. <b>2016</b> , 1303, 49-67	29
814	The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. <b>2016</b> , 36, 114-31	54
813	Entorhinal cortex: a good biomarker of mild cognitive impairment and mild Alzheimer's disease. <b>2016</b> , 27, 185-95	33
812	Investigating virtual reality navigation in amnesic mild cognitive impairment using fMRI. <b>2016</b> , 23, 196-217	15
811	Systems Biology of Alzheimer's Disease. <b>2016</b> ,	4
810	The brain interstitial system: Anatomy, modeling, in vivo measurement, and applications. <b>2017</b> , 157, 230-246	110
809	Magnesium ion influx reduces neuroinflammation in A $\beta$ precursor protein/Presenilin 1 transgenic mice by suppressing the expression of interleukin-1 $\beta$ <b>2017</b> , 14, 451-464	31
808	CSF A $\beta$ - an excellent but complicated Alzheimer's biomarker - a route to standardisation. <b>2017</b> , 467, 27-33	82
807	Amyloid- $\beta$ and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. <b>2017</b> , 22, 306-311	86
806	Monoaminergic neuropathology in Alzheimer's disease. <b>2017</b> , 151, 101-138	137
805	Stem Cells in Alzheimer's Disease Therapy. <b>2017</b> , 49-64	

804	Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid $\beta$ 1-42 in CSF for the Diagnosis of Alzheimer's Disease. <b>2017</b> , 16, 1228-1238		23
803	Personalized protein corona on nanoparticles and its clinical implications. <b>2017</b> , 5, 378-387		165
802	Targeting $\beta$ -amyloid plaques and oligomers: development of near-IR fluorescence imaging probes. <b>2017</b> , 9, 179-198		15
801	Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease. <b>2017</b> , 7, 40263		32
800	Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. <b>2017</b> , 7, e995		48
799	Sleep and Neurodegeneration: A Critical Appraisal. <b>2017</b> , 151, 1375-1386		25
798	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <b>2017</b> , 6, 143-151		43
797	The effects of different familial Alzheimer's disease mutations on APP processing in vivo. <b>2017</b> , 9, 9		22
796	Astroglial activation and altered amyloid metabolism in human repetitive concussion. <i>Neurology</i> , <b>2017</b> , 88, 1400-1407	6.5	27
795	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. <b>2017</b> , 133, 839-856		107
794	Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. <b>2017</b> , 306, 25-30		16
793	Accuracy of cerebrospinal fluid A $\beta$ 1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunoassay. <b>2017</b> , 55, 1545-1554		12
792	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <b>2017</b> , 13, 993-1003		35
791	The protective role of plant biophenols in mechanisms of Alzheimer's disease. <b>2017</b> , 47, 1-20		56
790	A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. <b>2017</b> , 20, 107-118		84
789	Applying fluid biomarkers to Alzheimer's disease. <b>2017</b> , 313, C3-C10		35
788	Changes of Cerebrospinal Fluid Peptides due to Tauopathy. <b>2017</b> , 58, 507-520		5
787	A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. <b>2017</b> , 20, 1052-1061		228



786	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <b>2017</b> , 1598, 101-115	11
785	Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition. <b>2017</b> , 58, 829-840	22
784	Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. <b>2017</b> , 12, 39	69
783	Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. <b>2017</b> , 58, 821-828	8
782	How the cognitive reserve interacts with $\beta$ -amyloid deposition in mitigating FDG metabolism: An observational study. <b>2017</b> , 96, e5876	8
781	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. <b>2017</b> , 58, 14-29	66
780	Medical Ethics, Prediction, and Prognosis. <b>2017</b> ,	1
779	Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. <b>2017</b> , 88, 883-888	16
778	Antibody-Mimetic Peptoid Nanosheet for Label-Free Serum-Based Diagnosis of Alzheimer's Disease. <b>2017</b> , 29, 1700057	45
777	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <b>2017</b> , 57, 387-393	8
776	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. <b>2017</b> , 4, 226-235	40
775	Redox speciation of iron, manganese, and copper in cerebrospinal fluid by strong cation exchange chromatography - sector field inductively coupled plasma mass spectrometry. <b>2017</b> , 973, 25-33	34
774	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. <b>2017</b> , 74, 557-566	435
773	Amyloid- $\beta$ accumulation in the CNS in human growth hormone recipients in the UK. <b>2017</b> , 134, 221-240	67
772	Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?. <b>2017</b> , 57, 493-504	14
771	Generation and Partial Characterization of Rabbit Monoclonal Antibody to Amyloid- $\beta$ Peptide 1-37 (A $\beta$ 7). <b>2017</b> , 57, 135-145	
770	Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid. <b>2017</b> , 95, 2005-2024	24
769	Clinical validity of cerebrospinal fluid A $\beta$ 42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <b>2017</b> , 52, 196-213	73

768	The Effects of Gene Mutations on 'Default' Mode Network in 'Familial' Alzheimer's Disease. <b>2017</b> , 56, 327-334	7
767	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. <b>2017</b> , 51, 104-112	115
766	Expanding the cerebrospinal fluid endopeptidome. <b>2017</b> , 17, 1600384	23
765	Transcriptional and epigenetic phenomena in peripheral blood cells of monozygotic twins discordant for alzheimer's disease, a case report. <b>2017</b> , 372, 211-216	20
764	Colorimetric sandwich immunosensor for A $\beta$ (1-42) based on dual antibody-modified gold nanoparticles. <b>2017</b> , 243, 792-799	45
763	Tau protein (MAPT) as a possible biochemical marker of traumatic brain injury in postmortem examination. <b>2017</b> , 280, 1-7	20
762	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. <b>2017</b> , 11, 1700100	19
761	Plasma Amyloid- $\beta$ Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. <b>2017</b> , 60, 977-987	26
760	Genetic and Pharmacological Discovery for Alzheimer's Disease Using <i>Caenorhabditis elegans</i> . <b>2017</b> , 8, 2596-2606	35
759	Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. <b>2017</b> , 60, 1451-1459	58
758	Computational integration of nanoscale physical biomarkers and cognitive assessments for Alzheimer's disease diagnosis and prognosis. <b>2017</b> , 3, e1700669	14
757	Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology. <b>2017</b> , 158, 15-44	31
756	Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease. <b>2017</b> , 124, 1621-1625	22
755	A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. <b>2017</b> , 6, 15-24	141
754	Alzheimer's disease markers in the aged sheep ( <i>Ovis aries</i> ). <b>2017</b> , 58, 112-119	17
753	Alzheimer's disease CSF biomarkers: clinical indications and rational use. <b>2017</b> , 117, 591-602	57
752	F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. <b>2017</b> , 9, 1212-1223	124
751	Absolute Quantification of A $\beta$ 1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure. <b>2017</b> ,	3

750	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. <b>2017</b> , 24, 1326-e77	55
749	Advances in Personalized Nanotherapeutics. <b>2017</b> ,	10
748	CNS Drug Delivery for Diseases Eradication: An Overview. <b>2017</b> , 157-185	
747	Sensing of Alzheimer's Disease and Multiple Sclerosis Using Nano-Bio Interfaces. <b>2017</b> , 59, 1187-1202	29
746	Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay. <b>2017</b> , 6, 349-361	31
745	Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report. <b>2017</b> , 17, 102	41
744	Association between total-Tau and brain atrophy one year after first-ever stroke. <b>2017</b> , 17, 107	7
743	Ex vivo O-labeling mass spectrometry identifies a peripheral amyloid $\beta$ clearance pathway. <b>2017</b> , 12, 18	15
742	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, $\beta$ synuclein, and total tau in combination with A $\beta$ (1-42)/A $\beta$ (1-40). <b>2017</b> , 9, 40	12
741	Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease. <b>2017</b> , 5, 10	85
740	Current Proteomic Approaches Applied to Brain Function. <b>2017</b> ,	3
739	Early diagnosis of Alzheimer's disease using infrared spectroscopy of isolated blood samples followed by multivariate analyses. <b>2017</b> , 142, 1276-1284	45
738	Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. <b>2017</b> , 74, 41-49	89
737	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <b>2017</b> , 16, 66-75	201
736	Metabolomics and mitochondrial dysfunction in Alzheimer's disease. <b>2017</b> , 39, 295-300	3
735	CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. <b>2017</b> , 49, 138-144	46
734	Nutrition for the ageing brain: Towards evidence for an optimal diet. <b>2017</b> , 35, 222-240	120
733	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <b>2017</b> , 13, 59-71	70

732	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <b>2017</b> , 19, 154-160		10
731	Toward sensitive immuno-based detection of tau protein by surface plasmon resonance coupled to carbon nanostructures as signal amplifiers. <b>2017</b> , 93, 289-292		42
730	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. <b>2017</b> , 74, 1492-1501		67
729	Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease. <b>2018</b> , 61, 571-580		26
728	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. <b>2017</b> ,		1
727	PET Tau and Amyloid- $\beta$ Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. <b>2017</b> , 60, 283-293		44
726	Multi-view visual saliency-based MRI classification for alzheimer's disease diagnosis. <b>2017</b> ,		2
725	Biomarkers and prognostication in traumatic brain injury. <b>2017</b> , 04, S2-S5		1
724	GENETIC DISORDER ALZHEIMER. <b>2017</b> , 10, 36		
723	Peptoids: tomorrow's therapeutics. <b>2017</b> , 251-280		6
722	Perspective, Summary, and Directions for Future Research on Alzheimer's Disease. <b>2017</b> , 361-386		
721	Using Multifunctional Peptide Conjugated Au Nanorods for Monitoring $\beta$ -amyloid Aggregation and Chemo-Photothermal Treatment of Alzheimer's Disease. <b>2017</b> , 7, 2996-3006		56
720	A Single-Use, In Vitro Biosensor for the Detection of T-Tau Protein, A Biomarker of Neuro-Degenerative Disorders, in PBS and Human Serum Using Differential Pulse Voltammetry (DPV). <b>2017</b> , 7,		36
719	Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 289	5-3	15
718	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and A $\beta$ Pathology in Non-demented Individuals. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 306	5-3	22
717	Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 356	5-3	36
716	Study on Analysis of Peripheral Biomarkers for Alzheimer's Disease Diagnosis. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 328	4-1	26
715	Biomarkers for Alzheimer's Disease. <b>2017</b> , 247-277		

714	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <b>2017</b> , 2017, 7935406	17
713	Biomarcadores y Marcadores de Imagen de la Enfermedad de Alzheimer. <b>2017</b> , 35, 864-869	1
712	Biomarkers in Traumatic Brain Injury. <b>2017</b> , 587-591	1
711	The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease. <b>2017</b> , 12, e0185239	22
710	Immunotherapy for the Treatment of Alzheimer's Disease. <b>2017</b> , 331-359	
709	No added diagnostic value of non-phosphorylated tau fraction (p-tau) in CSF as a biomarker for differential dementia diagnosis. <b>2017</b> , 9, 49	11
708	Dynamic changes of oligomeric amyloid $\beta$ levels in plasma induced by spiked synthetic A $\beta$ <b>2017</b> , 9, 86	33
707	Preclinical effects of APOE $\epsilon$ on cerebrospinal fluid A $\beta$ 42 concentrations. <b>2017</b> , 9, 87	16
706	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. <b>2017</b> , 9, 95	243
705	Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease. <b>2017</b> , 65-135	1
704	Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread. <b>2017</b> , 8, 46177-46190	15
703	From Imaging Agents to Theranostic Drugs in Alzheimer's Disease. <b>2017</b> , 74-106	
702	Blood-based immunoassay of tau proteins for early diagnosis of Alzheimer's disease using surface plasmon resonance fiber sensors.. <b>2018</b> , 8, 7855-7862	23
701	Biomarkers for Preclinical Alzheimer's Disease. <b>2018</b> ,	
700	Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers. <b>2018</b> , 62, 1507-1518	16
699	Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease. <b>2018</b> , 141, 1470-1485	52
698	Cognitive and neuroimaging features and brain $\beta$ -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <b>2018</b> , 17, 335-346	113
697	Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients. <b>2018</b> , 232, 134-138	3

696	CSF biomarkers of Alzheimer's disease concord with amyloid- $\beta$ PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <b>2018</b> , 14, 1470-1481	266
695	Low Cerebrospinal Fluid A $\beta$ 42 and A $\beta$ 40 are Related to White Matter Lesions in Cognitively Normal Elderly. <b>2018</b> , 62, 1877-1886	9
694	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. <b>2018</b> , 9, 1591-1606	13
693	Findings from the Swedish Study on Familial Alzheimer's Disease Including the APP Swedish Double Mutation. <b>2018</b> , 64, S491-S496	4
692	Amyloid blood biomarker detects Alzheimer's disease. <b>2018</b> , 10,	100
691	Plasma Amyloid- $\beta$ (A $\beta$ 42) Correlates with Cerebrospinal Fluid A $\beta$ 42 in Alzheimer's Disease. <b>2018</b> , 62, 1857-1863	61
690	PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease. <b>2018</b> , 62, 1519-1525	14
689	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <b>2018</b> , 14, 535-562	3155
688	The Past and the Future of Alzheimer's Disease Fluid Biomarkers. <b>2018</b> , 62, 1125-1140	69
687	Precision pharmacology for Alzheimer's disease. <b>2018</b> , 130, 331-365	60
686	Species fractionation in a case-control study concerning Parkinson's disease: Cu-amino acids discriminate CSF of PD from controls. <b>2018</b> , 49, 164-170	16
685	Neurogranin as a predictor of memory and executive function decline in MCI patients. <i>Neurology</i> , <b>2018</b> , 90, e887-e895	6.5 32
684	A Longitudinal Study of Total and Phosphorylated $\beta$ -Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. <b>2018</b> , 61, 1541-1553	20
683	Progress and Challenges in the Diagnosis of Dementia: A Critical Review. <b>2018</b> , 9, 446-461	16
682	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. <b>2018</b> , 125, 673-679	20
681	Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium. <b>2017</b> , 7, 374-385	20
680	AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. <b>2018</b> , 14, 811-823	26
679	Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer's disease. <b>2018</b> , 14, 1	62

678	Inferior Parietal Cortex Hypoperfusion is the Most Specific Imaging Marker for AD Patients With Positive CSF Biomarker Assays in a Memory Clinic in France. <b>2018</b> , 32, 89-93		1
677	Comparing F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 90, e388-e395	6.5	62
676	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. <b>2018</b> , 5, 162-171		23
675	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A $\beta$ total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. <b>2018</b> , 14, 492-501		71
674	Altered structural network organization in cognitively normal individuals with amyloid pathology. <b>2018</b> , 64, 15-24		20
673	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <b>2018</b> , 10, 8		62
672	Targeted Mass Spectrometry-Based Assays for Relative Quantification of 30 Brain-Related Proteins and Their Clinical Applications. <b>2018</b> , 17, 2282-2292		10
671	Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. <b>2018</b> , 182, 12-20		34
670	Cerebrospinal fluid $\beta$ -amyloid and neurofilament light relate to white matter hyperintensities. <b>2018</b> , 68, 18-25		29
669	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. <b>2018</b> , 62, 965-992		57
668	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. <b>2018</b> , 64, S647-S657		5
667	Cerebrospinal fluid $\beta$ -synuclein contributes to the differential diagnosis of Alzheimer's disease. <b>2018</b> , 14, 1052-1062		27
666	An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice. <b>2018</b> ,		23
665	Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. <b>2018</b> , 221-252		1
664	2018 Alzheimer's disease facts and figures. <b>2018</b> , 14, 367-429		1154
663	Label-free detection of $\beta$ -amyloid peptides (A $\beta$ 40 and A $\beta$ 42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease. <b>2018</b> , 10, 6361-6368		43
662	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. <b>2018</b> , 64, S47-S105		84
661	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <b>2018</b> , 8, 4260		17

660	Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches. <b>2018</b> , 80, 34-53	17
659	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <b>2018</b> , 83, 447-455	62
658	CSF biomarkers in delirium: a systematic review. <b>2018</b> , 33, 1479-1500	32
657	Role of Vital Trace Elements in Nanocurcumin-Centered Formulation: A Novel Approach to Resuscitate the Immune System. <b>2018</b> , 182, 265-277	5
656	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. <b>2018</b> , 10,	305
655	Upward drift in cerebrospinal fluid amyloid $\beta$ 42 assay values for more than 10 years. <b>2018</b> , 14, 62-70	36
654	The Emergence of a New Conceptual Framework for Alzheimer's Disease. <b>2018</b> , 62, 1059-1066	30
653	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease. <b>2018</b> , 28, 3638-3649 <sup>21</sup>	
652	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <b>2018</b> , 19, 244-328	148
651	CSF A $\beta$ but not p-Tau differentiates aMCI from SCI. <b>2018</b> , 1678, 27-31	6
650	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. <b>2018</b> , 12, 1700131	62
649	Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. <b>2018</b> , 114, 3-9	45
648	APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <b>2018</b> , 33, 289-297	24
647	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- $\beta$ 1-42 Analysis Results. <b>2018</b> , 64, 576-585	76
646	Cerebrospinal fluid in the dementias. <b>2017</b> , 146, 85-97	9
645	Are the brain's vascular and Alzheimer pathologies additive or interactive?. <b>2018</b> , 31, 147-152	20
644	CSF neurofilament light concentration is increased in presymptomatic mutation carriers. <i>Neurology</i> , <b>2018</b> , 90, e157-e163	6.5 10
643	Increased midlife triglycerides predict brain $\beta$ -amyloid and tau pathology 20 years later. <i>Neurology</i> , <b>2018</b> , 90, e73-e81	6.5 44



642	Detection of $\beta$ -Amyloid by Sialic Acid Coated Bovine Serum Albumin Magnetic Nanoparticles in a Mouse Model of Alzheimer's Disease. <b>2018</b> , 14, 1701828	26
641	Tau in neurodegenerative disease. <b>2018</b> , 6, 175	78
640	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. <b>2018</b> , 63, 373-381	9
639	Diagnostiek van dementie: praktijkvariatie in Nederlandse geheugenpoliklinieken. <b>2018</b> , 22, 137-146	2
638	Diagnostiek van de ziekte van Alzheimer. <b>2018</b> , 22, 172-179	
637	A Novel Perspective Linkage Between Kidney Function and Alzheimer's Disease. <b>2018</b> , 12, 384	21
636	. <b>2018</b> , 6, 58213-58221	32
635	Protein Profiling in Serum and Cerebrospinal Fluid Following Complex Surgery on the Thoracic Aorta Identifies Biological Markers of Neurologic Injury. <b>2018</b> , 11, 503-516	3
634	Dementia. <b>2018</b> , 159, 303-321	9
633	Blood and cerebrospinal fluid biomarkers. <b>2018</b> , 158, 217-233	7
632	Chronic traumatic encephalopathy: fluid biomarkers. <b>2018</b> , 158, 323-333	9
631	The current state of biomarkers of mild traumatic brain injury. <b>2018</b> , 3,	56
630	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. <b>2018</b> , 10, 124	156
629	Metabolomic investigations in cerebrospinal fluid of Parkinson's disease. <b>2018</b> , 13, e0208752	30
628	Ethical Arguments Concerning the Use of Alzheimer's Disease Biomarkers in Individuals with No or Mild Cognitive Impairment: A Systematic Review and Framework for Discussion. <b>2018</b> , 66, 1309-1322	11
627	Current state of Alzheimer's fluid biomarkers. <b>2018</b> , 136, 821-853	236
626	Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundaci� ACE Healthy Brain Initiative (FACEHBI). <b>2018</b> , 10, 119	25
625	Serum Ethanolamine Plasmalogen and Urine Myo-Inositol as Cognitive Decline Markers. <b>2018</b> , 87, 69-111	3

624	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 639-652	15	257
623	Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics. <b>2018</b> , 158, 376-401		20
622	Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset. <b>2018</b> , 66, 229-237		19
621	HIV Neuroinfection and Alzheimer's Disease: Similarities and Potential Links?. <b>2018</b> , 12, 307		32
620	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. <b>2018</b> , 10, 782-790		11
619	Brain-originated peptides as possible biochemical markers of traumatic brain injury in cerebrospinal fluid post-mortem examination. <b>2018</b> , 56, 97-103		9
618	Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons. <b>2018</b> , 121, 38-49		13
617	A $\beta$ 42/A $\beta$ 40 and A $\beta$ 42/A $\beta$ 8 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study. <b>2018</b> , 65, 1377-1383		13
616	The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. <b>2018</b> , 10,		68
615	CSF pro-orexin and amyloid- $\beta$ 8 expression in Alzheimer's disease and frontotemporal dementia. <b>2018</b> , 72, 171-176		15
614	Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. <b>2018</b> , 8, 13276		59
613	Particular CSF sphingolipid patterns identify iNPH and AD patients. <b>2018</b> , 8, 13639		15
612	Atomic Force Microscopy Analysis of EPPS-Driven Degradation and Reformation of Amyloid- $\beta$ Aggregates. <b>2018</b> , 2, 41-49		8
611	A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models. <b>2018</b> , 11,		13
610	Introduction. <b>2018</b> , 1-24		
609	Profiling biomarkers of traumatic axonal injury: From mouse to man. <b>2018</b> , 171, 6-20		18
608	Drug-Abuse Nanotechnology: Opportunities and Challenges. <b>2018</b> , 9, 2288-2298		4
607	Small molecule biomarkers in Alzheimer's disease. <b>2018</b> , 25, D404		5

606	Sex-specific genetic predictors of Alzheimer’s disease biomarkers. <b>2018</b> , 136, 857-872	48
605	Commutability of the certified reference materials for the standardization of $\beta$ -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and $\beta$ -amyloid 1-40 measurements. <b>2018</b> , 56, 2058-2066	23
604	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: A review. <b>2018</b> , 14, 1313-1333	61
603	Adenosine Receptors in Alzheimer’s Disease. <b>2018</b> , 259-280	3
602	A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers. <b>2018</b> , 13, 843-856	37
601	Biomarkers for Alzheimer’s disease: current status and prospects for the future. <b>2018</b> , 284, 643-663	278
600	Exosomes as possible spread factor and potential biomarkers in Alzheimer’s disease: current concepts. <b>2018</b> , 12, 1025-1033	14
599	Plasma amyloid- $\beta$ levels, cerebral atrophy and risk of dementia: a population-based study. <b>2018</b> , 10, 63	25
598	Cerebrospinal fluid tau, A $\beta$ and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. <b>2018</b> , 14, 1159-1170	64
597	Circadian Rhythm and Alzheimer’s Disease. <b>2018</b> , 6,	18
596	Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer’s Biomarker. <b>2018</b> , 18,	19
595	Real-Time Tau Protein Detection by Sandwich-Based Piezoelectric Biosensing: Exploring Tubulin as a Mass Enhancer. <b>2018</b> , 18,	7
594	The TRPM2 channel nexus from oxidative damage to Alzheimer’s pathologies: An emerging novel intervention target for age-related dementia. <b>2018</b> , 47, 67-79	25
593	Non-SELEX isolation of DNA aptamers for the homogeneous-phase fluorescence anisotropy sensing of tau Proteins. <b>2018</b> , 1038, 173-181	33
592	Addition of the A $\beta$ 42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment. <b>2018</b> , 10, 33	36
591	Molecular biomarkers of Alzheimer’s disease: progress and prospects. <b>2018</b> , 11,	109
590	In Situ Monitoring the Aggregation Dynamics of Amyloid- $\beta$ Protein A $\beta$ 42 in Physiological Media via a Raman-Based Frequency Shift Method.. <b>2018</b> , 1, 814-824	11
589	Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings. <b>2018</b> , 136, 1242-1248	126

588	Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date. <b>2018</b> , 17, 4072-4084		3
587	Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study. <b>2018</b> , 46, 90-99		6
586	Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease. <b>2018</b> , 15, 938-950		10
585	Greater tau load and reduced cortical thickness in APOE $\epsilon$ -negative Alzheimer's disease: a cohort study. <b>2018</b> , 10, 77		36
584	S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid- $\beta$ Plaques and Tau in Brain Biopsies. <b>2018</b> , 64, 171-179		12
583	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <b>2018</b> , 125, 1373-1379	14	
582	Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice. <b>2018</b> , 13, e0190212		6
581	Neuronal Enriched Extracellular Vesicle Proteins as Biomarkers for Traumatic Brain Injury. <b>2019</b> , 36, 975-987		25
580	High-precision plasma $\beta$ -amyloid 42/40 predicts current and future brain amyloidosis. <i>Neurology</i> , <b>2019</b> , 93, e1647-e1659	6.5	245
579	Primary Care Mental Health in Older People. <b>2019</b> ,		2
578	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. <b>2019</b> , 251-298		1
577	Multivariate Statistical Analysis of Surface Enhanced Raman Spectra of Human Serum for Alzheimer's Disease Diagnosis. <b>2019</b> , 9, 3256		20
576	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <b>2019</b> , 84, 225-234		16
575	Cortical auditory evoked potentials in mild cognitive impairment: Evidence from a temporal-spatial principal component analysis. <b>2019</b> , 56, e13466		3
574	N-Glycan Profile of Cerebrospinal Fluids from Alzheimer's Disease Patients Using Liquid Chromatography with Mass Spectrometry. <b>2019</b> , 18, 3770-3779		22
573	Thalamic volume loss as an early sign of amnesic mild cognitive impairment. <i>Journal of Clinical Neuroscience</i> , <b>2019</b> , 68, 168-173	2.2	8
572	Supervised pathway analysis of blood gene expression profiles in Alzheimer's disease. <b>2019</b> , 84, 98-108		5
571	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease.. <b>2019</b> , 14 Pt B, 74-82		1

570	Characterization of Cerebrospinal Fluid BACE1 Species. <b>2019</b> , 56, 8603-8616		4
569	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. <b>2019</b> , 7, 120		35
568	Robust and Universal SERS Sensing Platform for Multiplexed Detection of Alzheimer's Disease Core Biomarkers Using PAapt-AuNPs Conjugates. <b>2019</b> , 4, 2140-2149		45
567	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2019</b> , 24, 101954	5-3	19
566	Autophagy-Mediated Secretory Pathway is Responsible for Both Normal and Pathological Tau in Neurons. <b>2019</b> , 70, 667-680		23
565	Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 1008	4-1	28
564	Nanoparticle-mediated approaches for Alzheimer's disease pathogenesis, diagnosis, and therapeutics. <b>2019</b> , 314, 125-140		24
563	EEG time signature in Alzheimer's disease: Functional brain networks falling apart. <i>NeuroImage: Clinical</i> , <b>2019</b> , 24, 102046	5-3	21
562	Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study. <b>2019</b> , 8,		13
561	Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 297	5-3	11
560	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <b>2019</b> , 11, e111170		113
559	Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 1036	4-1	5
558	Meta-Analysis of Gene Expression Changes in the Blood of Patients with Mild Cognitive Impairment and Alzheimer's Disease Dementia. <b>2019</b> , 20,		15
557	Detection of early-stage Alzheimer's pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients. <b>2019</b> , 14, e0225178		8
556	Cofilin 2 in Serum as a Novel Biomarker for Alzheimer's Disease in Han Chinese. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 214	5-3	6
555	Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. <b>2019</b> , 2044, 27-50		8
554	Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer's disease. <b>2019</b> , 47, 4968-4980		9
553	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <b>2019</b> , 11, 82		26

552	Screening for Alzheimer's Disease Using Saliva: A New Approach Based on Machine Learning and Raman Hyperspectroscopy. <b>2019</b> , 71, 1351-1359		22
551	[11C]PIB PET Is Associated with the Brain Biopsy Amyloid- $\beta$ Load in Subjects Examined for Normal Pressure Hydrocephalus. <b>2019</b> , 67, 1343-1351		11
550	Predicting diagnosis and cognition with F-AV-1451 tau PET and structural MRI in Alzheimer's disease. <b>2019</b> , 15, 570-580		43
549	A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer's Disease. <b>2018</b> , 11, 483		10
548	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. <b>2019</b> , 491, 81-84		7
547	Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <b>2019</b> , 72, 30-38		37
546	Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease. <b>2019</b> , 14, e0218561		9
545	Precision Nanomedicine Development Based on Specific Opsonization of Human Cancer Patient-Personalized Protein Coronas. <b>2019</b> , 19, 4692-4701		44
544	SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , <b>2019</b> , 15, 419-427	15	22
543	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. <b>2019</b> , 90, 1117-1123		32
542	NFL is a marker of treatment response in children with SMA treated with nusinersen. <b>2019</b> , 266, 2129-2136		61
541	Identification of Alzheimer's Disease Autoantibodies and Their Target Biomarkers by Phage Microarrays. <b>2019</b> , 18, 2940-2953		24
540	Blood-based diagnostics of Alzheimer's disease. <b>2019</b> , 19, 613-621		8
539	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. <b>2019</b> , 69, 1213-1220		8
538	The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?. <b>2019</b> , 72, 15-23		3
537	Complex Differential Diagnosis of Cognitive Impairments. <b>2019</b> , 49, 422-428		
536	Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions. <i>Neurology</i> , <b>2019</b> , 92, e2717-e2726	6.5	8
535	Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. <b>2019</b> , 69, 551-559		3

534	Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases. <b>2019</b> , 140, 177-183		1
533	Advantages and disadvantages of the use of the CSF Amyloid $\beta$ (A $\beta$ ) 42/40 ratio in the diagnosis of Alzheimer's Disease. <b>2019</b> , 11, 34		145
532	Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers. <b>2019</b> , 72, 24-29		1
531	Light-Induced Pupillary Responses in Alzheimer's Disease. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 360	4.1	33
530	Bridging the Gap between Alzheimer's Disease and Alzheimer's-like Diseases in Animals. <b>2019</b> , 20,		10
529	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <b>2019</b> , 9, e024498		5
528	Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis. <b>2019</b> , 494, 74-78		11
527	Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study. <b>2019</b> , 68, 723-733		11
526	Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). <b>2019</b> , 7, 34		15
525	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <b>2019</b> , 15, 655-665		48
524	Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. <b>2019</b> , 14, e0212815		4
523	Acyl-Alkyl-Phosphatidylcholines are Decreased in Saliva of Patients with Alzheimer's Disease as Identified by Targeted Metabolomics. <b>2019</b> , 68, 583-589		9
522	Granulovacuolar Degeneration in Brains of Senile Cynomolgus Monkeys. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 50	5.3	5
521	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2019</b> , 22, 101767	5.3	16
520	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <b>2019</b> , 15, 742-753		50
519	Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid- $\beta$ and tau. <b>2019</b> , 80, 11-20		54
518	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. <b>2019</b> , 90, 740-746		14
517	Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF A $\beta$ levels. <b>2019</b> , 11, 281-285		29

516	Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and F-FDG-PET imaging. <i>NeuroImage: Clinical</i> , <b>2019</b> , 22, 101771	53	62
515	Carbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer's disease?. <b>2019</b> , 143, 186-203		28
514	Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects. <b>2019</b> , 72, 39-51		13
513	The Alzheimer Precision Medicine Initiative. <b>2019</b> , 68, 1-24		48
512	Cerebrospinal fluids from Alzheimer's disease patients exhibit neurotoxic effects on neuronal cell cultures. <b>2019</b> , 50, 1994-2006		3
511	Biomarkers for Concussion: The Need and the Prospects for the Near Future. <b>2019</b> , 638-645		
510	Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. <b>2019</b> , 14, 10		30
509	Early Diagnosis of Alzheimer's Disease. <b>2019</b> , 7-12		
508	Lymphocytes, Platelets, Erythrocytes, and Exosomes as Possible Biomarkers for Alzheimer's Disease Clinical Diagnosis. <b>2019</b> , 1118, 71-82		11
507	Association between physical activity and dementia's risk factors in patients with Parkinson's disease. <b>2019</b> , 126, 319-325		16
506	A Nanoplasmonic Biosensor for Ultrasensitive Detection of Alzheimer's Disease Biomarker Using a Chaotropic Agent. <b>2019</b> , 4, 595-602		27
505	Pyroglutamation of amyloid- $\beta$ -42 (A $\beta$ -42) followed by A $\beta$ 1-40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. <b>2019</b> , 294, 6719-6732		30
504	A promising structural magnetic resonance imaging assessment in patients with preclinical cognitive decline and diabetes mellitus. <b>2019</b> , 234, 16838-16846		0
503	Long-Term Storage Effects on Stability of A $\beta$ , A $\beta$ and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays. <b>2019</b> , 9, 77-86		9
502	Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. <b>2019</b> , 126, 339-348		10
501	Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease. <i>Brain Science Advances</i> , <b>2019</b> , 5, 94-105	2	3
500	Oligomeric A $\beta$ in the monkey brain impacts synaptic integrity and induces accelerated cortical aging. <b>2019</b> ,		41
499	Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. <b>2019</b> , 11, 91		31



498	Integrative Metabolomic and Metallomic Analysis in a Case-Control Cohort With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 331	53	9
497	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. <b>2019</b> , 168, 3-23		11
496	Nanomaterials towards Biosensing of Alzheimer's Disease Biomarkers. <b>2019</b> , 9,		31
495	Evaluation of hippocampal volume and serum brain-derived neurotrophic factor as potential diagnostic markers of conversion from amnesic mild cognitive impairment to Alzheimer disease: A STROBE-compliant article. <b>2019</b> , 98, e16604		9
494	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys A $\beta$ (1-42), pTau and tTau CSF immunoassays. <b>2019</b> , 9, 19024		50
493	Collecting Digital Biomarkers on Cognitive Health Through Computer Vision and Gameplay: an Image Processing Toolkit for Card Games. <b>2019</b> ,		6
492	Critical Steps to be Taken into Consideration Before Quantification of $\beta$ -Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. <b>2019</b> , 8, 129-145		6
491	Neurophysiological Markers of Alzheimer's Disease: Quantitative EEG Approach. <b>2019</b> , 8, 37-55		23
490	De ziekte van Alzheimer. <b>2019</b> , 35, 17-30		
489	Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. <b>2019</b> , 33, 99-106		24
488	Astrocyte Biomarkers in Alzheimer's Disease. <b>2019</b> , 25, 77-95		108
487	HOTMAQ: A Multiplexed Absolute Quantification Method for Targeted Proteomics. <b>2019</b> , 91, 2112-2119		11
486	The Gothenburg H70 Birth cohort study 2014-16: design, methods and study population. <b>2019</b> , 34, 191-209		44
485	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. <b>2019</b> , 151, 397-416		18
484	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. <b>2019</b> , 76, 187-193		42
483	The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD. <b>2019</b> , 34, 415-419		5
482	Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies. <b>2019</b> , 195, 186-198		77
481	Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease. <b>2019</b> , 176, 3464-3474		15

480	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. <b>2019</b> , 490, 98-101		11
479	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <b>2019</b> , 46, 1152-1163		23
478	Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. <i>Neurology</i> , <b>2019</b> , 92, e395-e405	6.5	16
477	Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. <b>2019</b> , 76, 125-132		64
476	Associations between tau, A $\beta$ and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , <b>2019</b> , 92, e601-e612	6.5	125
475	Association of PTHrP levels in CSF with Alzheimer's disease biomarkers.. <b>2019</b> , 14 Pt B, 124-129		3
474	Growing synergy of nanodiamonds in neurodegenerative interventions. <b>2019</b> , 24, 584-594		11
473	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. <b>2019</b> , 90, 157-164		113
472	Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <b>2019</b> , 15, 55-64		50
471	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. <b>2019</b> , 15, 232-244		95
470	Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome. <b>2019</b> , 79, 711-715		9
469	Is Olfactory Epithelium Biopsy Useful for Confirming Alzheimer's Disease?. <b>2019</b> , 128, 184-192		4
468	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <b>2019</b> , 137, 279-296		79
467	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <b>2019</b> , 420, 136-144		12
466	Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults. <b>2019</b> , 13, 41-52		22
465	The impact of social networks and $\beta$ on dementia among older adults: tests of possible interactions. <b>2020</b> , 24, 395-404		7
464	Reappraisal of FDA approved drugs against Alzheimer's disease based on differential gene expression and protein interaction network analysis: an in silico approach. <b>2020</b> , 38, 3972-3989		3
463	Dementia and CSF-biomarkers for Alzheimer's disease predict mortality after acute hip fracture. <b>2020</b> , 64, 93-103		11

462	Prediction of Alzheimer's disease diagnosis within 14 years through A $\beta$ misfolding in blood plasma compared to APOE4 status, and other risk factors. <b>2020</b> , 16, 283-291	15
461	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. <b>2020</b> , 20, 10	22
460	Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease. <b>2020</b> , 715, 134658	8
459	A Machine Learning Approach to Identify a Circulating MicroRNA Signature for Alzheimer Disease. <b>2020</b> , 5, 15-28	9
458	Cerebrospinal fluid and blood biomarkers of status epilepticus. <b>2020</b> , 61, 6-18	13
457	Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer's disease. <b>2020</b> , 76, 24-30	2
456	Face-Name Associative Memory Performance Among Cognitively Healthy Individuals, Individuals With Subjective Memory Complaints, and Patients With a Diagnosis of aMCI. <b>2020</b> , 11, 2173	0
455	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. <i>Neurology</i> , <b>2021</b> , 96, e193-e202	6.5 8
454	Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. <b>2020</b> , 6,	36
453	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. <b>2020</b> , 10,	10
452	microRNA-Based Biomarkers in Alzheimer's Disease (AD). <b>2020</b> , 14, 585432	28
451	Cerebrospinal Fluid and Serum d-Serine Levels in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis. <b>2020</b> , 9,	3
450	Comparison of ELISA- and SIMOA-based quantification of plasma A $\beta$ ratios for early detection of cerebral amyloidosis. <b>2020</b> , 12, 162	21
449	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <b>2020</b> , 57, 4667-4691	14
448	Fluid Biomarkers for Chronic Traumatic Encephalopathy. <b>2020</b> , 40, 411-419	2
447	Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer's Disease Differential Diagnosis. <b>2020</b> , 9,	6
446	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. <b>2020</b> , 95, 143-153	17
445	The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment. <b>2020</b> , 10,	8

444	Sleep spindle abnormalities related to Alzheimer's disease: a systematic mini-review. <b>2020</b> , 75, 37-44	4
443	Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer's Disease. <b>2020</b> , 20,	16
442	Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease. <b>2020</b> , 21,	3
441	Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events. <b>2020</b> , 34, 2577-2586	6
440	Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. <b>2020</b> , 10,	5
439	First amyloid $\beta$ 1-42 certified reference material for re-calibrating commercial immunoassays. <b>2020</b> , 16, 1493-1503	20
438	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. <b>2020</b> , 10,	10
437	Current Biomarkers for Alzheimer's Disease: From CSF to Blood. <b>2020</b> , 10,	13
436	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. <b>2020</b> , 15, e0233820	3
435	Insight into the divergent role of TRAIL in non-neoplastic neurological diseases. <b>2020</b> , 24, 11070-11083	3
434	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A $\beta$ pathology are detected. <b>2020</b> , 12, e12921	67
433	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <b>2020</b> , 12, 168	2
432	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <b>2020</b> , 11, 6252	15
431	Prognostic value of cerebrospinal fluid biomarkers in mild cognitive impairment due to Alzheimer disease. <b>2020</b> ,	
430	Multimodal MRI Based Classification and Prediction of Alzheimer's Disease Using Random Forest Ensemble. <b>2020</b> ,	4
429	Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer's Disease. <b>2020</b> , 10,	1
428	Increased apolipoprotein E and decreased TNF- $\alpha$ in the cerebrospinal fluid of nondemented APOE- $\epsilon$ 4 carriers. <b>2020</b> , 40, 201-205	4
427	No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study. <b>2020</b> , 20, 174	14

426	The implications of different approaches to define AT(N) in Alzheimer disease. <i>Neurology</i> , <b>2020</b> , 94, e2233-e2244	33	44
425	An automated alert system based on the p-Tau/Tau ratio to quickly inform health professionals upon a suspected case of sporadic Creutzfeldt-Jakob disease. <b>2020</b> , 415, 116971		2
424	Patients with Alzheimer's Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid. <b>2020</b> , 75, 289-298		5
423	Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study. <b>2020</b> , 76, 941-953		3
422	Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers. <b>2020</b> , 161, 59-71		11
421	Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism. <i>Frontiers in Aging Neuroscience</i> , <b>2020</b> , 12, 126	5-3	4
420	Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnesic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. <b>2020</b> , 76, 681-689		12
419	Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. <b>2020</b> , 12, e12033		2
418	New Directions in Psychiatry. <b>2020</b> ,		
417	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <b>2020</b> , 15, 36		16
416	Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula () and Routine Western Medicine. <b>2020</b> , 26, 212-218		1
415	Innovative IgG Biomarkers Based on Phage Display Microbial Amyloid Mimotope for State and Stage Diagnosis in Alzheimer's Disease. <b>2020</b> , 11, 1013-1026		5
414	Biochemical Markers in Alzheimer's Disease. <b>2020</b> , 21,		24
413	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. <b>2020</b> , 12, 30		6
412	Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions. <i>Frontiers in Aging Neuroscience</i> , <b>2020</b> , 12, 56	5-3	7
411	Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults. <b>2020</b> , 74, 965-974		8
410	Predisposition to Alzheimer's and Age-Related Brain Pathologies by PM2.5 Exposure: Perspective on the Roles of Oxidative Stress and TRPM2 Channel. <b>2020</b> , 11, 155		14
409	A transistor-based label-free immunosensor for rapid detection of tau protein. <b>2020</b> , 159, 112129		13

408	Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database. <b>2020</b> , 416, 116989	8
407	Nanomaterial synthesis, an enabler of amyloidosis inhibition against human diseases. <b>2020</b> , 12, 14422-14440	13
406	Blood and cerebrospinal fluid biomarkers for Alzheimer's disease. <b>2020</b> , 5, 15-15	2
405	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. <b>2020</b> , 49, 5446-5472	25
404	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <b>2020</b> , 26, 379-386	292
403	Biomarkers and Their Role in Detection of Biomolecules. <b>2020</b> , 73-94	2
402	Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in a Chinese Cohort. <b>2020</b> , 36, 696-704	12
401	Intermediate flortaucipir uptake is associated with A $\beta$ -PET and CSF tau in asymptomatic adults. <i>Neurology</i> , <b>2020</b> , 94, e1190-e1200	6.5 18
400	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. <b>2020</b> , 66, 587-597	8
399	Fingerprinting Alzheimer's Disease by H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. <b>2020</b> , 19, 1696-1705	17
398	Adaptive sparse learning using multi-template for neurodegenerative disease diagnosis. <b>2020</b> , 61, 101632	10
397	A survey on machine and statistical learning for longitudinal analysis of neuroimaging data in Alzheimer's disease. <b>2020</b> , 189, 105348	15
396	Choroid plexus volume is associated with levels of CSF proteins: relevance for Alzheimer's and Parkinson's disease. <b>2020</b> , 89, 108-117	9
395	Salivary biomarkers in Alzheimer's disease. <b>2020</b> , 24, 3437-3444	12
394	The relationship between blood lipids and plasma amyloid beta is depend on blood pressure: a population-based cross-sectional study. <b>2020</b> , 19, 8	3
393	Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study. <b>2020</b> , 15, 25	21
392	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <b>2020</b> , 11, 1683	133
391	Design principles and fundamental understanding of biosensors for amyloid- $\beta$ detection. <b>2020</b> , 8, 6179-6196	17

390	Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. <b>2020</b> , 80, 313-317	21
389	Relationship between cortical iron and tau aggregation in Alzheimer's disease. <b>2020</b> , 143, 1341-1349	42
388	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <b>2020</b> , 74, 1189-1201	19
387	Regional [F]lortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <b>2020</b> , 47, 2866-2878	11
386	Dissecting the Structural Organization of Multiprotein Amyloid Aggregates Using a Bottom-Up Approach. <b>2020</b> , 11, 1447-1457	3
385	Beta-Amyloid-Dependent miRNAs as Circulating Biomarkers in Alzheimer's Disease: a Preliminary Report. <b>2020</b> , 70, 871-877	7
384	Circadian and sleep dysfunction in Alzheimer's disease. <b>2020</b> , 60, 101046	51
383	Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. <b>2020</b> , 131, 1287-1310	61
382	Immunoaffinity biosensor for neurofilament light chain detection and its use in Parkinson's diagnosis. <b>2020</b> , 256, 114545	5
381	CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease. <b>2020</b> , 91, 5-14	13
380	Nasal delivery of a CRMP2-derived CBD3 adenovirus improves cognitive function and pathology in APP/PS1 transgenic mice. <b>2020</b> , 13, 58	1
379	Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. <b>2021</b> , 26, 897-906	26
378	Impact of intrauterine hypoxia on adolescent and adult cognitive function in rat offspring: sexual differences and the effects of spermidine intervention. <b>2021</b> , 42, 361-369	2
377	Hippocampal subregional volume changes in elders classified using positron emission tomography-based Alzheimer's biomarkers of $\beta$ -amyloid deposition and neurodegeneration. <b>2021</b> , 99, 481-501	3
376	Fluorescent peptide nanoparticles to detect amyloid-beta aggregation in cerebrospinal fluid and serum for Alzheimer's disease diagnosis and progression monitoring. <b>2021</b> , 405, 126733	7
375	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <b>2021</b> , 17, 755-767	31
374	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <b>2021</b> , 78, 149-156	62
373	Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. <b>2021</b> , 112, 82-91	8

372	Analyzing the effect of APOE on Alzheimer's disease progression using an event-based model for stratified populations. <b>2021</b> , 227, 117646	3
371	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. <b>2021</b> , 79, 729-741	4
370	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. <b>2021</b> , 265, 1-97	0
369	Introduction. <b>2021</b> , 1-10	
368	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <b>2021</b> , 13, 2	5
367	Nanoarchitected Bioconjugates and Bioreceptors Mediated Surface Plasmon Resonance Biosensor for Diagnosis of Alzheimer's Disease: Development and Future Prospects. <b>2021</b> , 1-31	5
366	Abeta CSF LC-MS. <b>2021</b> , 55-69	
365	Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. <b>2021</b> , 4, 63	8
364	Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond.. <b>2021</b> , 11, 20403-20422	0
363	Lateralized Deficits in Motor, Sensory, and Olfactory Domains in Dementia. <b>2021</b> , 79, 1033-1040	0
362	Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. <b>2021</b> , 16, 10	35
361	Ecto-GPR37: a potential biomarker for Parkinson's disease. <b>2021</b> , 10, 8	3
360	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <b>2021</b> , 13, 38	4
359	Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases?. <b>2021</b> , 11,	7
358	Deciphering Alzheimer's Disease Pathogenic Pathway: Role of Chronic Brain Hypoperfusion on p-Tau and mTOR. <b>2021</b> , 79, 1381-1396	1
357	Investigating Different Forms of Hydrogen Sulfide in Cerebrospinal Fluid of Various Neurological Disorders. <b>2021</b> , 11,	2
356	Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 646901	5-3 5
355	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid $\beta$ and tau. <b>2021</b> , 17, 1575-1582	12



354	Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. <b>2021</b> , 22,	18
353	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. <b>2021</b> , 13, 68	35
352	A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. <b>2021</b> , 17, 933-945	14
351	Proteomics Landscape of Alzheimer's Disease. <b>2021</b> , 9,	2
350	Biological Features of Reversion from Mild Cognitive Impairment to Normal Cognition: A Study of Cerebrospinal Fluid Markers and Brain Volume. <b>2021</b> , 5, 179-186	1
349	Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study. <b>2021</b> , 80, 1389-1394	
348	Plasma amyloid $\beta$ levels in Alzheimer's disease and cognitively normal controls in Syrian population. <b>2021</b> , 35, 19	1
347	Recent advances in pre-clinical diagnosis of Alzheimer's disease. <b>2021</b> , 1	
346	Independent information from PET, CSF and plasma biomarkers of tau pathology in Alzheimer's disease.	
345	Advances in aptamer-based nanomaterials for separation and analysis of non-genetic biomarkers in biofluids. <b>2021</b> , 64, 932-947	1
344	Synergistic Association between Plasma A $\beta$ and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. <b>2021</b> , 12, 1376-1383	2
343	Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease. <b>2021</b> , 13, 84	10
342	Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. <b>2021</b> , 13, 79	
341	Biomarkers in neurological disorders: a fast-growing market. <b>2021</b> , 3, fcab086	1
340	Profiling of Cerebrospinal Fluid Lipids and Their Relationship with Plasma Lipids in Healthy Humans. <b>2021</b> , 11,	2
339	Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data. <b>2021</b> , 3, fcab091	2
338	Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application. <b>2021</b> , 81, 19-32	1
337	Predict Alzheimer's disease using hippocampus MRI data: a lightweight 3D deep convolutional network model with visual and global shape representations. <b>2021</b> , 13, 104	8

336	Plasma phosphatidylcholines and vitamin B12/folate levels are possible prognostic biomarkers for progression of Alzheimer's disease. <b>2021</b> , 147, 111264	3
335	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study. <b>2021</b> , 17, 1832-1842	0
334	An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS.	
333	□Amyloid in Cerebrospinal Fluid: How to Keep It Floating (Not Sticking) by Standardization of Preanalytic Processes and Collection Tubes. <b>2021</b> , 6, 1155-1164	1
332	Protein and Imaging Biomarkers in the Eye for Early Detection of Alzheimer's Disease. <b>2021</b> , 5, 375-387	4
331	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <b>2021</b> , 8, 1456-1470	3
330	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A $\beta$ 42/A $\beta$ 40 and p-tau. <b>2021</b> ,	12
329	Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. <b>2021</b> , 15, 679199	9
328	Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis. <b>2021</b> , 1	2
327	Critical Appraisal of Amyloid Lowering Agents in AD. <b>2021</b> , 21, 39	9
326	Elevated norepinephrine metabolism is linked to cortical thickness in the context of Alzheimer's disease pathology. <b>2021</b> , 102, 17-22	4
325	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <b>2021</b> , 290, 583-601	15
324	Plasma Levels of Amyloid- $\beta$ Peptides and Tau Protein in Mexican Patients with Alzheimer's Disease. <b>2021</b> , 82, S271-S281	0
323	Phage-Derived and Aberrant HaloTag Peptides Immobilized on Magnetic Microbeads for Amperometric Biosensing of Serum Autoantibodies and Alzheimer's Disease Diagnosis.	2
322	Enhanced Catalytic Activity Induced by the Nanostructuring Effect in Pd Decoration onto Doped Ceria Enabling an Origami Paper Analytical Device for High Performance of Amyloid- $\beta$ Bioassay. <b>2021</b> , 13, 33937-33947	3
321	The potential diagnostic accuracy of circulating microRNAs for Alzheimer's disease: A meta-analysis. <b>2021</b> ,	2
320	An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis. <b>2021</b> , 144, 640-646	1
319	A Concise Overview of Biosensing Technologies for the Detection of Alzheimer's Disease Biomarkers. <b>2021</b> ,	2

3 <sup>18</sup>	Two human metabolites rescue a <i>C. elegans</i> model of Alzheimer's disease via a cytosolic unfolded protein response. <b>2021</b> , 4, 843	1
3 <sup>17</sup>	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <b>2021</b> , 13, e14398	8
3 <sup>16</sup>	Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study. <b>2021</b> , 28, 1099-1107	2
3 <sup>15</sup>	Advances with Long Non-Coding RNAs in Alzheimer's Disease as Peripheral Biomarker. <b>2021</b> , 12,	5
3 <sup>14</sup>	Platelet APP Processing: Is It a Tool to Explore the Pathophysiology of Alzheimer's Disease? A Systematic Review. <b>2021</b> , 11,	
3 <sup>13</sup>	Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood. <b>2021</b> , 12, 700587	0
3 <sup>12</sup>	Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia. <b>2021</b> , 82, 781-790	1
3 <sup>11</sup>	Profound changes in cerebrospinal fluid proteome and metabolic profile are associated with congenital hydrocephalus. <b>2021</b> , 41, 3400-3414	1
3 <sup>10</sup>	Towards point-of-care diagnosis of Alzheimer's disease: Multi-analyte based portable chemiresistive platform for simultaneous detection of $\beta$ -amyloid (1-40) and (1-42) in plasma. <b>2021</b> , 186, 113294	3
3 <sup>09</sup>	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. <b>2021</b> , 13, 138	4
3 <sup>08</sup>	Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study. <b>2021</b> , 52, e499-e516	6
3 <sup>07</sup>	Bias-generating factors in biofluid amyloid- $\beta$ measurements for Alzheimer's disease diagnosis. <b>2021</b> , 11, 287-295	1
3 <sup>06</sup>	MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology. <b>2021</b> , 8, 1817-1830	1
3 <sup>05</sup>	Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer's Disease. <b>2021</b> , 1	2
3 <sup>04</sup>	Biobanking for Neurodegenerative Diseases: Challenge for Translational Research and Data Privacy. <b>2021</b> , 10738584211036693	1
3 <sup>03</sup>	Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. <b>2021</b> , 159, 211-233	8
3 <sup>02</sup>	Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis. <b>2021</b> , 159, 61-77	2
3 <sup>01</sup>	MicroRNAs in Huntington's Disease: Diagnostic Biomarkers or Therapeutic Agents?. <b>2021</b> , 15, 705348	3

300	Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years. <b>2021</b> , 82, 951-964	1
299	Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. <b>2021</b> , 82, 1045-1054	1
298	Sensorineural hearing loss may lead to dementia-related pathological changes in hippocampal neurons. <b>2021</b> , 156, 105408	2
297	The Amyloid- $\beta$ Pathway in Alzheimer's Disease. <b>2021</b> ,	63
296	Diagnosi clinicolaboratoristica della malattia di Alzheimer. <b>2021</b> , 21, 1-15	
295	Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. <b>2021</b> , 1	2
294	Retinal Amyloid Imaging for Screening Alzheimer's Disease. <b>2021</b> , 83, 927-934	8
293	Large-scale proteome analysis of CSF implicates altered glucose metabolism in Alzheimer's disease.	0
292	Evidence-based complementary and alternative medicine bioinformatics approach through network pharmacology and molecular docking to determine the molecular mechanisms of Erjing pill in Alzheimer's disease. <b>2021</b> , 22, 1252	0
291	Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington's disease.	
290	The Effect of Systemic Inflammation on Cognitive Function and Neurodegenerative Disease. <b>2021</b> , 164-189	
289	Regional relationships between CSF VEGF levels and Alzheimer's disease brain biomarkers and cognition. <b>2021</b> , 105, 241-251	1
288	F-florbetapir PET as a marker of myelin integrity across the Alzheimer's disease spectrum. <b>2021</b> , 1	2
287	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <b>2021</b> ,	11
286	Alternative platelet activation pathways and their role in neurodegenerative diseases. <b>2021</b> , 159, 105512	1
285	Brain injury markers in new-onset seizures in adults: A pilot study. <b>2021</b> , 92, 62-67	2
284	Label-free detection of $\beta$ -Amyloid (1-42) in plasma using electrospun SnO <sub>2</sub> nanofiber based electro-analytical sensor. <b>2021</b> , 346, 130522	5
283	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. <b>2021</b> , 48, 2259-2271	4

282	Tau-proximity ligation assay reveals extensive previously undetected pathology prior to neurofibrillary tangles in preclinical Alzheimer's disease. <b>2021</b> , 9, 18	7
281	Regional structural hypo- and hyperconnectivity of frontal-striatal and frontal-thalamic pathways in behavioral variant frontotemporal dementia. <b>2018</b> , 39, 4083-4093	13
280	Protein Microarrays in Neurodegenerative Diseases. <b>2017</b> , 43-62	2
279	Soluble Amyloid Precursor Proteins in Blood: Methods and Challenges. <b>2018</b> , 179-187	1
278	Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. <b>2018</b> , 1750, 31-66	23
277	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <b>2018</b> , 1750, 139-155	10
276	Determination of Cerebrospinal Fluid Proteome Variations by Isobaric Labeling Coupled with Strong Cation-Exchange Chromatography and Tandem Mass Spectrometry. <b>2019</b> , 2044, 155-168	3
275	Amyloid Oligomers, Protofibrils and Fibrils. <b>2019</b> , 93, 471-503	5
274	Classification Systems of Mental Disorders: Where Did We Go Wrong?. <b>2020</b> , 193-203	0
273	Platelets in Neurological Disorders. <b>2017</b> , 513-530	5
272	Antidementia. <b>2013</b> , 331-342	1
271	Development of Nanoparticle-Enabled Protein Biomarker Discovery: Implementation for Saliva-Based Traumatic Brain Injury Detection. <b>2015</b> , 121-129	2
270	Amyloid-beta peptide detection via aptamer-functionalized nanowire sensors exploiting single-trap phenomena. <b>2020</b> , 154, 112053	25
269	Proteomics: methodologies and applications to the study of human diseases. <b>2012</b> , 58, 366-375	4
268	Diagnostic Assessment in Primary Progressive Aphasia: An Illustrative Case Example. <b>2020</b> , 29, 1833-1849	5
267	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <b>2016</b> , 139, 2528-39	45
266	Preoperative cognitive assessment of the elderly surgical patient: a call for action. <b>2011</b> , 114, 1265-8	48
265	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.	1

264	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.	0
263	Altered Bile Acid Profile in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Neuroimaging and CSF Biomarkers.	3
262	Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer's Disease.	11
261	Amyloid- $\beta$ misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. <b>2020</b> , 12, 169	10
260	Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression. <b>2018</b> , 7, 1012	19
259	A $\beta$ 40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. <b>2010</b> , 5, e15725	82
258	CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. <b>2012</b> , 7, e30525	158
257	BACE1 inhibition induces a specific cerebrospinal fluid $\beta$ -amyloid pattern that identifies drug effects in the central nervous system. <b>2012</b> , 7, e31084	60
256	Metabolite profiling of Alzheimer's disease cerebrospinal fluid. <b>2012</b> , 7, e31501	122
255	No diagnostic value of plasma clusterin in Alzheimer's disease. <b>2012</b> , 7, e50237	32
254	Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease. <b>2013</b> , 8, e53587	41
253	Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. <b>2013</b> , 8, e63644	271
252	Evaluating amyloid- $\beta$ oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. <b>2013</b> , 8, e66381	93
251	Effects of NR1H3 genetic variation on the expression of liver X receptor $\beta$ and the progression of Alzheimer's disease. <b>2013</b> , 8, e80700	13
250	Non-invasive screening for Alzheimer's disease by sensing salivary sugar using <i>Drosophila</i> cells expressing gustatory receptor (Gr5a) immobilized on an extended gate ion-sensitive field-effect transistor (EG-ISFET) biosensor. <b>2015</b> , 10, e0117810	26
249	Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. <b>2015</b> , 10, e0125614	99
248	Striatal Atrophy in the Behavioural Variant of Frontotemporal Dementia: Correlation with Diagnosis, Negative Symptoms and Disease Severity. <b>2015</b> , 10, e0129692	16
247	High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid. <b>2015</b> , 10, e0135365	44

246	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. <b>2015</b> , 10, e0135458	66
245	Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease. <b>2016</b> , 11, e0150672	56
244	Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients. <b>2016</b> , 11, e0159099	43
243	Altered Blood Biomarker Profiles in Athletes with a History of Repetitive Head Impacts. <b>2016</b> , 11, e0159929	29
242	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. <b>2016</b> , 11, e0163479	35
241	Enhanced Detection of Low-Abundance Human Plasma Proteins by Integrating Polyethylene Glycol Fractionation and Immunoaffinity Depletion. <b>2016</b> , 11, e0166306	16
240	Targeted metabolomic profiling of cerebrospinal fluid from patients with progressive multifocal leukoencephalopathy. <b>2020</b> , 15, e0242321	1
239	The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. <b>2014</b> , 1, 181-202	39
238	PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. <b>2016</b> , 3, 243-259	49
237	The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. <b>2011</b> , 49, 375-83	66
236	Biomarkers in Alzheimer's disease: Evaluation of platelets, hemoglobin and vitamin B12. <b>2020</b> , 14, 35-40	3
235	[Comprehensive early diagnosis of cognitive impairment]. <b>2015</b> , 115, 72-79	10
234	[Perspectives of the diagnosis of Alzheimer's disease using optic coherent tomography]. <b>2017</b> , 117, 112-117	2
233	Fasting blood glucose and cerebrospinal fluid Alzheimer's biomarkers in non-diabetic cognitively normal elders: the CABLE study. <b>2020</b> , 12, 4945-4952	4
232	High pulse pressure is a risk factor for prodromal Alzheimer's disease: a longitudinal study. <b>2020</b> , 12, 18221-18237	2
231	Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies. <b>2017</b> , 8, 64745-64778	38
230	Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. <b>2018</b> , 9, 5614-5626	8
229	Identification of prefrontal cortex protein alterations in Alzheimer's disease. <b>2018</b> , 9, 10847-10867	19

228	A plasma proteolysis pathway comprising blood coagulation proteases. <b>2016</b> , 7, 40919-40938	15
227	Innate immune activation in Alzheimer's disease. <b>2018</b> , 6, 177	33
226	The application of weighted gene co-expression network analysis in identifying key modules and hub genes associated with disease status in Alzheimer's disease. <b>2019</b> , 7, 800	12
225	Blood-based Biomarkers of Alzheimer's Disease: The Long and Winding Road. <b>2020</b> , 26, 1300-1315	7
224	Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer's Disease and Correlation with Cerebral Hypoperfusion Pattern. <b>2019</b> , 16, 483-494	7
223	Plasma Clusterin as a Potential Biomarker for Alzheimer's Disease-A Systematic Review and Meta-analysis. <b>2019</b> , 16, 1018-1027	2
222	Strategies Targeting Soluble $\beta$ -Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer's Disease. <b>2019</b> , 16, 1132-1142	2
221	Exploring the Potential of Neuroproteomics in Alzheimer's Disease. <b>2020</b> , 20, 2263-2278	7
220	The Serum Amyloid $\beta$ Level in Multiple Sclerosis: A Case- Control Study. <b>2017</b> , 3, 214-221	1
219	Alzheimer's Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology. <b>2020</b> , 11,	5
218	Endogenous and Exogenous Factors in Hyperphosphorylation of Tau in Alzheimer's Disease*. <b>2012</b> , 39, 778-784	7
217	Body fluid biomarkers in Alzheimer's disease. <b>2015</b> , 3, 70	12
216	maxim extract attenuates abnormal Tau phosphorylation. <b>2018</b> , 13, 915-922	3
215	Biomarkers for the early diagnosis of Alzheimer's disease: The challenge of XXI century. <b>2013</b> , 02, 13-30	8
214	Recent progress and concerns in dementia: Distinguishing Alzheimer's disease and dementia with Lewy bodies via biochemical markers in the cerebrospinal fluid. <b>2012</b> , 02, 176-190	5
213	Platelets and Alzheimer's disease: Potential of APP as a biomarker. <b>2012</b> , 2, 102-113	36
212	Dendritic complexity change in the triple transgenic mouse model of Alzheimer's disease. <b>2020</b> , 8, e8178	3
211	Amyloid pathology but not APOE $\epsilon$ status is permissive for tau-related hippocampal dysfunction.. <b>2022</b> ,	0



- 210 Alzheimer Identification through DNA Methylation and Artificial Intelligence Techniques. **2021**, 9, 2482 0
- 209 Visual-Saliency-Based Abnormality Detection for MRI Brain Images—Alzheimer’s Disease Analysis. **2021**, 11, 9199 2
- 208 Herpes Simplex Virus 1 and 2 Infections during Differentiation of Human Cortical Neurons. **2021**, 13, 3
- 207 Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer’s Disease. **2021**, 18, 573-584 2
- 206 Preface: Mass spectrometry in Alzheimer disease: This is the Preface for the special issue "Mass Spectrometry in Alzheimer Disease". **2021**, 159, 207-210
- 205 Antidementiva. **2010**, 331-342
- 204 Antidementiva. **2011**, 339-350
- 203 Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics. **2012**, 341-354
- 202 Antidementiva. **2012**, 339-350
- 201 Peripheral Biomarkers of Oxidative Stress in Alzheimer’s Disease. **2013**, 185-199
- 200 Vers une nouvelle d’finition de la maladie d’Alzheimer. **2013**, 197, 143-156 0
- 199 Cerebral Amyloid Angiopathy. 135-161
- 198 Cardiovascular Proteomic Analysis. **2013**, 81-98
- 197 Impact of the IWG/Dubois Criteria for Alzheimer’s Disease in Imaging Studies. **2014**, 309-322
- 196 Therapie Psychischer Erkrankungen - Pages 1-91. **2014**, 1-91
- 195 Investigation. **2014**, 203-248
- 194 Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia. **2014**, 131-157
- 193 Biomarkers and Neurodegenerative Diseases: Promising Inroads Toward a Distant Goal. **2014**, 415-441

- 192 Alzheimer-Associated Pathology in the Extracellular Space. **2015**, 75-93 1
- 191 Therapie Psychischer Erkrankungen - Pages e1-e96. **2015**, e1-e96
- 190 Alzheimer's Disease and Other Neurodegenerative Disorders. **2015**, 329-351
- 189 Extracellular Vesicles and Neurological Diseases. **2015**, 33, 75-81
- 188 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. **2017**, 1-111
- 187 [Complex diagnostic of cognitive impairment]. **2017**, 117, 33-40 1
- 186 A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. 2
- 185 Quantitative analysis of synaptic pathology and neuroinflammation: an initial study in a female rhesus monkey model of the synaptic phase of Alzheimer's disease.
- 184 Biomarqueurs du liquide céphalo-rachidien dans la maladie d'Alzheimer. **2018**, 202, 307-320
- 183 . **2018**, 107, 127-144 0
- 182 Investigation. **2018**, 207-240
- 181 VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimer's Disease.
- 180 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. **2019**, 1-119
- 179 A New Biological Definition of Alzheimer's Disease: Introduction of 2018 National Institute on Aging-Alzheimer's Association Research Framework. **2019**, 37, 1-7 1
- 178 Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus. **2019**, 11, 53-58
- 177 ADsoluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression.
- 176 Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer. **2019**, 15,
- 175 Blood Pressure and T-Tau in Spinal Fluid Are Associated With Delayed Recall in Participants With Memory Complaints and Dementia of the Alzheimer's Type. *Frontiers in Aging Neuroscience*, **2021**, 13, 652510 5:3 1

174	Maladie d'Alzheimer ^ un stade pr̄coce : le r̄le central de l'imagerie. <b>2020</b> , 20, 120S11-120S18	
173	Linking gradient echo plural contrast imaging metrics of tissue microstructure with Alzheimer disease. <b>2020</b> , 507-519	
172	Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. <b>2020</b> , 35, e361	5
171	Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations.	
170	Censoring-robust time-dependent receiver operating characteristic curve estimators. <b>2021</b> , 40, 6885	1
169	Periphery Biomarkers for Objective Diagnosis of Cognitive Decline in Type 2 Diabetes Patients. <b>2021</b> , 9, 752753	1
168	Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. <b>2021</b> , 178, 1014-1025	1
167	Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data.	
166	Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. <b>2021</b> , 427-451	
165	The Neuropeptide Kyotorphin as a Possible Biomarker and Neuroprotective Agent in Alzheimer's Disease. <b>2020</b> , 13, 8-18	
164	microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). <b>2012</b> , 3, 365-73	146
163	Tau is reduced in AD plasma and validation of employed ELISA methods. <b>2012</b> , 1, 99-106	35
162	Molecular approaches in obesity studies. <b>2013</b> , 6, S23-31	3
161	Comparison of two methods for the analysis of CSF A $\beta$ and tau in the diagnosis of Alzheimer's disease. <b>2014</b> , 3, 143-51	6
160	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Emergence of the Solution to an Important Unmet Need. <b>2013</b> , 24, 97-104	3
159	Longitudinal Data in Patients with Niemann-Pick Type C Disease Under Combined High Intrathecal and Low Intravenous Dose of 2-hydroxypropyl- $\beta$ -cyclodextrin. <b>2021</b> , 18, 11-16	1
158	Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future. <b>2021</b> , 209, 114479	0
157	Current progress in aptamer-based sensing tools for ultra-low level monitoring of Alzheimer's disease biomarkers. <b>2022</b> , 197, 113789	4

156	Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. <b>2021</b> , 11, 22675	4
155	Anaemia and cerebrospinal fluid biomarkers of Alzheimer's pathology in cognitively normal elders: the CABLE study. <b>2021</b> , 21, 454	0
154	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <b>2021</b> ,	2
153	Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease. <b>2021</b> ,	3
152	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. <b>2021</b> , 22,	0
151	Gfap and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: a post hoc analysis of the COMACARE trial. <b>2021</b> ,	0
150	Par-4 in Neuronal Death and Survival in Alzheimer's Disease and Other Neurodegenerative Diseases. <b>2021</b> , 215-245	
149	The Neurochemistry of Alzheimer's Disease: One of the Most Common Causes of Reduced Capability in the Adult Population. <b>2022</b> , 81-93	
148	Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention.. <b>2021</b> , 74, 101544	3
147	Highly sensitive surface-enhanced Raman scattering-based immunosensor incorporating half antibody-fragment for quantitative detection of Alzheimer's disease biomarker in blood.. <b>2022</b> , 1195, 339445	4
146	Biomarkers and Precision Medicine in Alzheimer's Disease.. <b>2021</b> , 1339, 403-408	0
145	Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer's Disease and Neurodegeneration: Old Drugs, New Concerns.. <b>2021</b> , 11, 734881	
144	Pulsed Arterial Spin Labeling and Segmented Brain Volumetry in the Diagnostic Evaluation of Frontotemporal Dementia, Alzheimer's Disease and Mild Cognitive Impairment.. <b>2022</b> , 8, 229-244	0
143	Independent morphological variables correlate with Aging, Mild Cognitive Impairment, and Alzheimer's Disease.	0
142	Emerging Roles of Microfluidics in Brain Research: From Cerebral Fluids Manipulation to Brain-on-a-Chip and Neuroelectronic Devices Engineering.. <b>2022</b> ,	3
141	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 805135	4.1 1
140	Physiology, pathology and the biomolecular corona: the confounding factors in nanomedicine design.. <b>2022</b> ,	3
139	Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.. <b>2021</b> ,	0

138	Isotopic N,N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease.. <b>2022</b> , 257, 104507		0
137	Advances in aptamers against A $\beta$ and applications in A $\beta$ detection and regulation for Alzheimer's disease.. <b>2022</b> , 12, 2095-2114		3
136	Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons.. <b>2022</b> ,		0
135	Network-driven anomalous transport is a fundamental component of brain microvascular dysfunction.. <b>2021</b> , 12, 7295		4
134	Recent advances in understanding depressive disorder: Possible relevance to brain stimulation therapies.. <b>2022</b> , 270, 123-147		
133	Progress of Nanotechnology-Based Detection and Treatment of Alzheimer's Disease Biomarkers. <b>2022</b> , 47-88		
132	Brain Injury Biomarkers for Predicting Outcome After Cardiac Arrest. <b>2022</b> , 285-297		
131	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 783996	5-3	1
130	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.. <b>2022</b> ,		3
129	A Pathway-Specific Polygenic Risk Score is Associated with Tau Pathology and Cognitive Decline.. <b>2021</b> ,		0
128	Brain Injury Biomarkers for Predicting Outcome After Cardiac Arrest.. <b>2022</b> , 26, 81		1
127	Plasma A $\beta$ as a biomarker for predicting A $\beta$ -PET status in Alzheimer's disease: a systematic review with meta-analysis.. <b>2022</b> ,		0
126	Structural Plasticity of the Hippocampus in Neurodegenerative Diseases.. <b>2022</b> , 23,		3
125	Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications.. <b>2022</b> , 11,		0
124	Categorical predictive and disease progression modeling in the early stage of Alzheimer's disease.. <b>2022</b> , 109581		0
123	Using the ATN system as a guide for the neuropsychological assessment of Alzheimer's disease.. <b>2022</b> , 1-18		0
122	Deep learning-driven risk-based subtyping of cognitively impaired individuals.		
121	Assessing Causal Relationship Between Human Blood Metabolites and Five Neurodegenerative Diseases With GWAS Summary Statistics.. <b>2021</b> , 15, 680104		0

120	Validation of Plasma Amyloid- $\beta$ 42/40 for Detecting Alzheimer Disease Amyloid Plaques.. <i>Neurology</i> , <b>2021</b> ,	6.5	7
119	The effectiveness of adaptive working memory training on EEG and cognitive performance in Alzheimer disease. <b>2022</b> , 26, 19-36		
118	Alzheimer's Disease: A Silent Pandemic - A Systematic Review on the Situation and Patent Landscape of the Diagnosis.. <b>2022</b> ,		
117	Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview.. <b>2022</b> ,		1
116	Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview.. <b>2022</b> , 11,		0
115	Impact of Anti-amyloid- $\beta$ Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 870517	5.3	8
114	Use of Cognitive Testing, Questionnaires, and Plasma Biomarkers to Quantify Cognitive Impairment in an Aging Pet Dog Population.. <b>2022</b> ,		0
113	Image_1.JPEG. <b>2019</b> ,		
112	Table_1.DOCX. <b>2019</b> ,		
111	Table_2.XLSX. <b>2019</b> ,		
110	Table_3.XLSX. <b>2019</b> ,		
109	Table_4.XLSX. <b>2019</b> ,		
108	Table_5.XLSX. <b>2019</b> ,		
107	Table_6.XLSX. <b>2019</b> ,		
106	Table_7.XLSX. <b>2019</b> ,		
105	Data_Sheet_1.pdf. <b>2019</b> ,		
104	Table_1.xlsx. <b>2019</b> ,		
103	Table_2.xls. <b>2019</b> ,		

102 Data\_Sheet\_1.docx. **2019,**

101 Data\_Sheet\_2.xlsx. **2019,**

100 Bilingualism as a Contributor to Cognitive Reserve: What it Can do and What it Cannot do.. **2022,** 37, 15333175221091417 0

99 Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer’s Disease Diagnosis. **2022,** 12, 595 1

98 Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217.. **2022,** 14, 67 0

97 Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.. *Nature Reviews Neurology*, **2022,** 15 4

96 PERFORMANCE OF SYNUCLEIN RT-QUIC IN RELATION TO NEUROPATHOLOGICAL STAGING OF LEWY BODY DISEASE.

95 An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS. **2022,** 17, e0269157 0

94 Putative Involvement of Cytokine Modulation in the Development of Perioperative Neurocognitive Disorders. Volume 15, 5349-5360 0

93 Establishment of combined diagnostic models of Alzheimer’s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS). **2022,** 12, 1

92 Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. **2022,** 23, 6891 0

91 Alzheimer’s Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus. **2022,** 12, 935 0

90 Performance of Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. **2022,** 10, 2

89 Association between obstructive sleep apnea and Alzheimer’s disease-related blood and cerebrospinal fluid biomarkers: A meta-analysis. *Journal of Clinical Neuroscience*, **2022,** 102, 87-94 2.2 4

88 Western Agarose Native GeELution (WANGEL) with beta-amyloid and tau: Novel method to elute proteins or peptides using native agarose gels followed by Lumipulse assay. *MethodsX*, **2022,** 9, 101779 1.9

87 Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update. *Journal of Clinical Neurology (Korea)*, **2022,** 18, 401 1.7 2

86 Application of peptide biomarkers in life analysis based on liquid chromatography-mass spectrometry technology. *BioFactors*, 6.1 0

85 Population pharmacokinetic modeling of CSF to blood clearance: prospective tracer study of 161 patients under work-up for CSF disorders. *Fluids and Barriers of the CNS*, **2022,** 19, 7 0

84	Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials. <i>Neurology</i> , 10.1212/WNL.000000000200817	6.5	o
83	Clinical utility of fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis.		
82	The association of serum uric acid with cognitive impairment and ATN biomarkers. <i>Frontiers in Aging Neuroscience</i> , 14,	5.3	o
81	A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer's Disease. <i>Biomedicine</i> , 2022, 10, 1713	4.8	o
80	Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease. <i>Brain Science Advances</i> , 2019, 5, 94-105	2	
79	The unique effect of TDP-43 on hippocampal subfield morphometry and cognition. <i>NeuroImage: Clinical</i> , 2022, 103125	5.3	
78	Advances in Potential Cerebrospinal Fluid Biomarkers for Autoimmune Encephalitis: A Review. <i>Frontiers in Neurology</i> , 13,	4.1	o
77	Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease. <i>Pharmaceutics</i> , 2022, 14, 1532	6.4	o
76	Alteration of plasma metabolic profile and physical performance combined with metabolites is more sensitive to early screening for mild cognitive impairment. <i>Frontiers in Aging Neuroscience</i> , 14,	5.3	o
75	Neuropathology and emerging biomarkers in corticobasal syndrome. 2022, 93, 919-929		1
74	CSF biomarkers in patients with epilepsy in Alzheimer's disease: a nation-wide study. 2022, 4,		o
73	Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation. 2022, 8,		o
72	Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?. 14,		1
71	Alzheimer's Disease: Molecular Biology, Pathophysiology and Biomarkers. 2022, 88-98		
70	Oligoclonal M bands unveils occult inflammation in multiple sclerosis. 2022, 104118		
69	The genetic and environmental etiology of blood-based biomarkers related to risk of Alzheimer's Disease in a population-based sample of early old-age men.		
68	Sex specific EEG signatures associated with cerebrospinal fluid biomarkers in mild cognitive impairment. 2022,		o
67	Biomarkers in cerebrospinal fluid and blood aid diagnosis of dementia. 2023, 47-68		o



- 66 Research Progress of Biomarkers for the Di-agnosis of Alzheimer's Disease. **2022**, 12, 7882-7890 ○
- 65 A Retrospective Study on Clinical Assessment of Cognitive Impairment in a Swedish Cohort: Is There Inequality Between Natives and Foreign-Born?. **2022**, 1-10 ○
- 64 Plasma biomarkers and their correlation in adult children of parents with Alzheimer's disease. 14, ○
- 63 Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease. **2022**, 15, ○
- 62 The Feasibility of Early Alzheimer's Disease Diagnosis Using a Neural Network Hybrid Platform. **2022**, 12, 753 ○
- 61 LP-05 A Novel Targeted Prussian Blue-Based Nanomaterial for Inhibiting Oxidative Stress and A $\beta$  Aggregation of Alzheimer's Disease. **2022**, 368, S285 ○
- 60 Fluid biomarkers and risk of neurodegenerative disease in retired athletes with multiple concussions: results from the International Concussion and Head Injury Research Foundation Brain health in Retired athletes Study of Ageing and Impact-Related Neurodegenerative Disease (ICHIRF-BRAIN study). **2022**, 8, e001327 ○
- 59 Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. 1
- 58 Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer's disease. 14, 1
- 57 Dissecting the Inhibitory Mechanism of the B-Crystallin Domain against A $\beta$ 42 Aggregation and Its Effect on A $\beta$ 42 Protofibrils: A Molecular Dynamics Simulation Study. **2022**, 13, 2842-2851 ○
- 56 Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. 2
- 55 Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis. jnnp-2022-329530 1
- 54 Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease. 14, ○
- 53 Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer's Disease from Other Neurological Disorders. **2022**, 23, 10831 1
- 52 Inflamasi dalam Patologi Penyakit Alzheimer. **2020**, 33, 65-71 ○
- 51 Potential value of preoperative fasting blood glucose levels in the identification of postoperative delirium in non-diabetic older patients undergoing total hip replacement: The perioperative neurocognitive disorder and biomarker lifestyle study. 13, ○
- 50 Retinal Examinations Provides Early Warning of Alzheimer's Disease. **2022**, 1-17 ○
- 49 A head-to-head comparison between plasma pTau181 and tau-PET along the Alzheimer's disease continuum. jnumed.122.264279 ○

- 48 Is Mitochondria DNA Variation a Biomarker for AD?. **2022**, 13, 1789 ○
- 47 Peripheral Concentration of Amyloid- $\beta$  TAU Protein, and Neurofilament Light Chain as Markers of Cognitive Dysfunction Syndrome in Senior Dogs. **2022**, 3, 23-38 ○
- 46 Plasma adiponectin levels predict cognitive decline and cortical thinning in mild cognitive impairment with beta-amyloid pathology. **2022**, 14, ○
- 45 Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. **2022**, 1 ○
- 44 CSF 14-3-3 $\beta$ s associated with tau pathology and elevated across the Alzheimer $\beta$  disease continuum. ○
- 43 Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status. **2022**, 14, ○
- 42 Distinct brain pathologies associated with Alzheimer $\beta$  disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid- $\beta$  amyloidosis. ○
- 41 PET molecular imaging for pathophysiological visualization in Alzheimer $\beta$  disease. 1
- 40 Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy. **2022**, ○
- 39 Functionalized graphene-based electrochemical array sensors for the identification of distinct conformational states of Amyloid Beta in Alzheimer's disease. **2023**, 222, 114927 ○
- 38 Big Five, self-reported depression, and anxiety are predictive for Alzheimer $\beta$  disease. ○
- 37 Gray matter hypoperfusion is a late pathological event in the course of Alzheimer $\beta$  disease. 0271678X2211411 ○
- 36 Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer $\beta$  Disease. **2022**, 23, 15670 ○
- 35 Protective Alzheimer $\beta$  disease-associated APP A673T variant predominantly decreases sAPP $\beta$  levels in cerebrospinal fluid and 2D/3D cell culture models. ○
- 34 CSF 14-3-3 $\beta$ s associated with tau pathology and elevated across the Alzheimer $\beta$  disease continuum. ○
- 33 Association Between Acoustic Features and Neuropsychological Test Performance in the Framingham Heart Study: Observational Study. **2022**, 24, e42886 ○
- 32 Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer $\beta$  disease. ○
- 31 PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid  $\beta$ 42, and Phosphorylated Tau in the Elderly. **2022**, 12, 1681 ○

30	Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum. <b>2022</b> , 17,	0
29	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.	0
28	Plasma biomarker profiles in autosomal dominant Alzheimer's disease.	0
27	Research and Prospect of Blood Biomarkers for Alzheimer's Disease. <b>2023</b> , 13, 11-19	0
26	Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia. <b>2023</b> , 24, 1226	0
25	Use of the Laboratory in the Diagnostic Workup of Older Adults. <b>2022</b> ,	0
24	Stress and the risk of Alzheimer dementia: Can deconstructed engrams be rebuilt?.	0
23	Net benefit of diagnostic tests for multistate diseases: an indicator variables approach. 1-28	0
22	Machine-learning based strategy identifies a robust protein biomarker panel for Alzheimer's disease in cerebrospinal fluid.	0
21	CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum. <b>2023</b> , 2023, 1-9	0
20	Early Detection of Alzheimer's Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers. <b>2023</b> , 92, 1077-1091	0
19	Association between anxiety symptoms and Alzheimer's disease biomarkers in cognitively healthy adults: A systematic review and meta-analysis. <b>2023</b> , 166, 111159	0
18	Effect of Pathway-specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals.	0
17	Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer's Disease. <b>2023</b> , 34, 459-471	0
16	The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort.	1
15	Biomarkers: Role and Scope in Neurological Disorders.	0
14	Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging. <b>2023</b> , 13,	0
13	Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort. <b>2023</b> , 15,	0

- 12 Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease. ○
- 11 Nanotechnology for point-of-care (POC) diagnostics. **2023**, 249-272 ○
- 10 Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample. **2023**, 15, ○
- 9 Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults. **2023**, 13, ○
- 8 Detection and analysis of chiral molecules as disease biomarkers. ○
- 7 Enfermedad de Alzheimer. **2023**, 13, 4360-4371 ○
- 6 Protein fibril length in cerebrospinal fluid is increased in Alzheimer’s disease. **2023**, 6, ○
- 5 Prognostic value of cerebrospinal fluid biomarkers in mild cognitive impairment due to Alzheimer disease. **2023**, ○
- 4 Biomarkers of Alzheimer’s Disease: Past, Present and Future Clinical Use. **2023**, 100063 ○
- 3 Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity. **2023**, 6, e238214 ○
- 2 Construction of a microcavity-based microfluidic chip with simultaneous SERS quantification of dual biomarkers for early diagnosis of Alzheimer’s disease. **2023**, 261, 124677 ○
- 1 Alzheimer’s Disease-Related Phospho-Tau181 Signals Are Localized to Demyelinated Axons of Parvalbumin-Positive GABAergic Interneurons in an App Knock-In Mouse Model of Amyloid- $\beta$  Pathology. **2023**, 1-17 ○